

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Trans20: A longitudinal cohort study of the health and wellbeing of trans and gender diverse young people in Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032151
Article Type:	Protocol
Date Submitted by the Author:	05-Jun-2019
Complete List of Authors:	Tollit, Michelle; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Pace, Carmen; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Telfer , Michelle ; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Hoq, Monsurul ; Murdoch Children's Research Institute, Clinical Epidemiology and Biostatistics Unit Bryson, Janet ; Murdoch Childrens Research Institute Fulkoski, Nicholas ; Murdoch Childrens Research Institute Cooper, Charlie; Murdoch Childrens Research Institute Pang, Ken; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne
Keywords:	Sexual and gender disorders < PSYCHIATRY, PAEDIATRICS, MENTAL HEALTH

SCHOLARONE™  
Manuscripts

# Trans20: A longitudinal cohort study of the health and wellbeing of trans and gender diverse young people in Australia

**Authors:** Michelle A Tollit<sup>1,2,3</sup>, Carmen C Pace<sup>1,2,4</sup>, Michelle M Telfer<sup>1,2,4</sup>, Monsurul Hoq<sup>1</sup>, Janet Bryson<sup>1</sup>, Nicholas Fulkoski<sup>1</sup>, Charlie Cooper<sup>1</sup>, Ken Pang<sup>1,2,4,5,6</sup>

**Affiliations:**

1. Murdoch Children's Research Institute, Melbourne, Victoria, Australia
2. The Royal Children's Hospital, Department of Adolescent Medicine, Melbourne, Victoria, Australia
3. Melbourne Graduate School of Education, The University of Melbourne, Parkville, Victoria, Australia
4. Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
5. Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
6. The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

## To whom correspondence should be addressed:

Dr Michelle Tollit  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [michelle.tollit@mcri.edu.au](mailto:michelle.tollit@mcri.edu.au)  
Ph: +61 3 9345 6903

Dr Ken Pang  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [ken.pang@mcri.edu.au](mailto:ken.pang@mcri.edu.au)  
Ph: +61 3 9345 5986

## ABSTRACT

Introduction: Being transgender is frequently accompanied by gender dysphoria, which often co-exists with mental health concerns. Increased referrals of transgender and gender diverse (TGD) youth to gender clinics have been reported around the world (1-4). Nevertheless, there is limited empirical data on the presentation and outcomes of these patients, and there is an urgent need for more evidence to ensure optimal medical and psychosocial interventions. Here we describe Trans20, a longitudinal study of TGD patients attending a multidisciplinary paediatric gender service in Melbourne, Australia. Trans20 aims to understand the demographic and clinical characteristics of these patients, to document the natural history of gender diversity presenting in childhood, and to investigate long-term outcomes for those receiving interventions.

Methods and analysis: Trans20 is a prospective cohort study based on children and adolescents first seen at the Royal Children's Hospital Gender Service (RCHGS) between February 2017 and February 2020. Current estimates indicate the final sample size will be approximately 600. Patients and their parents complete online questionnaires prior to the first appointment with RCHGS and regularly thereafter as part of routine clinical care. Upon discharge from RCHGS patients are invited to continue undertaking questionnaires biennially. In this way, a naturally forming cohort study has been created. The primary outcomes include gender dysphoria, physical and mental health, schooling, family functioning and quality of life. Subgroup analyses based on factors such as gender identity, birth-assigned sex and treatment received will be performed using bivariate and multivariate modelling as appropriate, and relevant statistical methods will be applied for the repeated measures over time.

Ethics and dissemination: The Royal Children's Hospital Human Research Ethics Committee approved this study (#36323). Findings from Trans20 will have translational impact by informing future treatment guidelines and gender affirming healthcare practices, and will be disseminated through conferences and peer reviewed journals.

### Strengths and limitations of this study

- Multiple domains including gender, mental health, physical health, schooling, family functioning and quality of life will be prospectively documented in a large cohort of TGD children and adolescents.
- Trans20 will represent one of the largest and most comprehensive longitudinal studies of TGD young people in the world, with potential to make a significant contribution to better understanding and improving the health of TGD children and adolescents globally.
- The long term follow-up of pre-pubescent children will allow examination of the natural history of gender diversity from an early age in a clinically referred population, enabling clinicians to provide accurate prognostic information to patients and families, and therefore assist decision-making around social and legal transition for TGD young people.
- Due to ethical reasons, it is not possible to incorporate an untreated control group in the Trans20 study design; this will limit the potential to draw direct conclusions about the effectiveness of interventions but, where possible, measures with population-based data are used in Trans20 to compare outcomes of TGD youth with those of the general population.

## INTRODUCTION

In recent times there has been an increase in the number of individuals identifying as transgender (5) and those seeking gender affirming healthcare (6). This rise may in part be related to increased social acceptance of gender diversity and the growing recognition that being transgender is part of the continuum of gender diversity. Despite these shifts in societal attitudes, being transgender is frequently accompanied by gender dysphoria (GD). GD is the distress that arises when a person's birth-assigned sex does not match their gender identity. GD experienced in childhood and adolescence can be particularly challenging as young people are navigating a range of physical, social and emotional changes during this critical developmental period. Serious psychiatric disorders are very common, with rates of self-reported depression and anxiety diagnoses in TGD young people in Australia as high as 75% and 72% respectively, and 80% reporting ever self-harming and 48% ever attempting suicide (7). Experiences of bullying, physical assault, discrimination and social exclusion are also common for transgender individuals (7-10), and these experiences are likely to contribute to poor mental health.

Accompanying the rise in reported prevalence of TGD young people has been a rapid increase in referrals to specialist gender clinics across the Western world (1-4). Many TGD children and adolescents and their families seek help from healthcare professionals requesting support, advice and gender affirming psychosocial and medical treatments. Best practice clinical guidelines (11-13) promote a multidisciplinary approach to address the complex biopsychosocial needs of this group, and treatment is ideally tailored to a young person's developmental stage and individual needs. Psychosocial support is central to assist the young person and their parents to understand and explore their gender identity and, where appropriate, help to facilitate social transition, which may involve adoption of gender-affirming hairstyles, clothing, names, and pronouns. For children and adolescents, psychological support can also be an important intervention for treating co-existing mental health issues, while helping to navigate the relational, social and personal challenges associated with their gender identity. For children who have not reached puberty – some of whom present with significant GD as young as age three – medical intervention is not warranted, but for older children and adolescents, medical interventions may serve an important role alongside psychosocial support and can take several forms. First, medications known as GnRH analogues (“puberty blockers”) can help to prevent the development of undesired physical changes during puberty, which can trigger and/or exacerbate GD. Secondly, gender affirming hormones, namely oestrogen and testosterone, can help promote physical changes congruent with the young person's gender identity. Thirdly, surgical procedures, such as chest reconstructive surgery for transmasculine individuals (“top surgery”), are performed on adolescents in some centres (14, 15), while genital surgery is generally only performed after the age of majority.

Specific healthcare for TGD children and adolescents – including the use of medical interventions – is relatively new, having commenced only in the past two decades. Consequently, there is limited empirical data to inform best practice in important areas such as risk and protective factors, and the long-term safety and outcomes of medical interventions (12, 16, 17). Another key area lacking evidence is the natural history of gender diversity. While some parents of TGD youth report noticing signs of gender diversity from as young as age two (18), not all gender diverse children develop a transgender identity. Published literature reports that 45-88% of children with gender concerns in childhood go on to identify with their birth-assigned sex in adolescence and adulthood

(19-23) indicating that only some of these children report a transgender identity when older. A number of methodological, interpretative and ethical concerns have been raised about these studies (19), and they are now thought to underestimate the persistence of TGD identities from childhood to adolescence. Given this uncertainty, there is a clear need to better understand these trajectories in order to inform and guide decision making in this area for young people and their families.

Various research groups around the world have been attempting to fill these important knowledge gaps via longitudinal cohort studies of TGD children and adolescents. The longest running of these has been based at VU University Medical Centre in the Netherlands, which pioneered the use of medical interventions for TGD youth and has provided much of the currently available empirical data in the field (24). More recently, an NIH-funded study recently commenced in the US and is aiming to follow 280 transgender youth over five years (25). The study is recruiting across four separate clinical sites, each of which have their own treatment protocols and practices. There is a clear need for additional international cohorts to sit alongside these established studies.

This paper describes the creation of a new longitudinal study of TGD children and adolescents, known as Trans20. Following a large cohort of patients who have attended the state-wide Royal Children's Hospital Gender Service (RCHGS) in Melbourne, Australia, Trans20 is designed to synthesize prospectively-gathered clinical data collected from patients during their time with and after they leave the RCHGS. The RCHGS employs a consistent assessment and treatment approach to its trans healthcare, meaning that Trans20 is ideally placed to avoid the difficulties inherent in studies that recruit across multiple sites where treatment approaches may vary (25).

In the context of this background, the Trans20 study primarily aims to:

- i) Describe the demographic and clinical characteristics of TGD young people who attend healthcare services for gender-related concerns
- ii) Identify clinical outcomes following different types of gender-affirming interventions (both psychosocial and medical)
- iii) Identify risk and protective factors associated with physical and mental health outcomes of TGD children and adolescents
- iv) Characterize the natural history of TGD young people, including those who differ in their presentations.

Trans20 seeks to contribute to the evidence underpinning healthcare for TGD young people, and thus not only inform prognosis but also improve clinical management and decision making.

## **METHODS AND ANALYSIS**

### **Study design**

Trans20 is a prospective, longitudinal cohort study, with a sample comprising patients aged 3-17 years when first attending the RCHGS between February 2017 and February 2020. Online questionnaires are routinely administered as part of standard clinical care at RCHGS and are completed by patients and a nominated parent/primary caregiver prior to the first appointment with the service, and then at regular periods thereafter (Figure 1). Some questionnaires are also

1  
2  
3 administered by clinicians during the patients' clinical consultations, and these are referred to as  
4 "in-clinic questionnaires" hereafter. Patients who leave the service are invited to continue  
5 undertaking questionnaires biennially. In this way, a naturally forming cohort study has been  
6 created, and our intention is to continue follow-up over a 20-year period.  
7

## 8 9 **Study setting**

10  
11 This study is based at the RCHGS in Melbourne, Australia. The RCHGS provides publicly-funded  
12 assessment and gender affirming care to TGD young people throughout the state of Victoria.  
13 RCHGS staff come from a range of clinical specialties and disciplines including psychology,  
14 psychiatry, paediatrics, endocrinology, gynaecology, speech therapy and nursing. With  
15 approximately 250 new referrals each year, RCHGS is the largest multidisciplinary gender service  
16 for children and adolescents in Australia. Young people up to age 17 years who reside in Victoria  
17 and have concerns regarding their gender identity can be referred to RCHGS by their general  
18 practitioner. Patients subsequently enter the service via one of two pathways: the Under 8 clinic  
19 for those aged 7 years and below, or the First Assessment Single Session Triage (FASST) clinic  
20 for those aged 8 years and older. Patients attending the Under 8 clinic are assigned a mental health  
21 clinician for initial assessment and support, and those wishing to undertake a medical transition  
22 are later referred to a member of the paediatric team prior to onset of puberty. Patients attending  
23 the FASST clinic see a Clinical Nurse Consultant or an Adolescent Medicine fellow (doctor  
24 undergoing advanced pediatric training) for initial assessment and support; those who wish to  
25 receive further psychosocial support and/or medical intervention are subsequently seen in the  
26 Multidisciplinary Assessment Clinic (MDAC) (Figure 1). Regardless of which pathway a patient  
27 enters, they and their parents undertake an assessment which includes the completion of  
28 standardised questionnaires prior to their first appointment, and these assessments are repeated at  
29 regular (~12 monthly) intervals as patients continue to attend the service.  
30  
31  
32  
33

## 34 35 **Participants and eligibility**

36  
37 To be eligible for inclusion in Trans20, participants need to have attended an initial appointment  
38 with the RCHGS between February 2017 - February 2020, have completed at least one of the  
39 baseline questionnaires (i.e., patient questionnaire, parent questionnaire, or in-clinic  
40 questionnaire), and speak sufficient English to complete the questionnaires. Since patients can be  
41 referred to the RCHGS at any age before 18 years, participants are expected to range in age from  
42 3-17 years at study entry. Based on those meeting eligibility for involvement in Trans20 in the  
43 first two years, it is expected that the Trans20 cohort will comprise approximately 600 participants  
44 over the three-year enrollment period.  
45  
46  
47

## 48 49 **Ethics, recruitment and consent**

50  
51 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
52 the conduct of this study (#36323). As previously outlined, questionnaires are completed by  
53 patients and parents as part of routine clinical care at RCHGS, and this information will be  
54 analysed under a clinical audit framework. As Trans20 is designed to prospectively collect data  
55 from patients beyond their time with the RCHGS, long-term follow up of patients who leave the  
56  
57  
58  
59



RCHGS requires specific consent. Consent is obtained using a multi-step procedure, from parents for those aged under 18 years, and from young people themselves once they are aged 18 years or older. At the time of undertaking assessments with the RCHGS, permission to contact patients and their families about the Trans20 study in the future is prospectively collected. Following discharge, those who have provided consent to be contacted are then invited to continue to undertake assessments. For patients who have left the service and are under 18 years, an email with parent and participant information statements as well as questionnaire links are sent to the nominated parent, who are asked to pass the relevant documentation to their child if they consent to them being involved. Patients who have left the service and are 18 years or older are sent these directly via email. Under each of these scenarios, completion of the online questionnaires provides implied consent. Consent to contact treating clinicians to obtain physical health information will also be sought for those who no longer attend the RCHGS.

### **Data collection and storage**

Parent and patient questionnaires are administered via LimeSurvey, an online, open source, survey web application (26), supported by the RCH for clinical use. Separate parent and patient questionnaire links are sent to a parent email address, and parents and patients complete the questionnaires online. Questionnaires are administered approximately one month prior to patients' initial appointment with the service, and then at approximately 12 month intervals throughout their RCHGS episode of care. Information on community supports are provided at the end of all questionnaires.

In-clinic questionnaires – which cover topics such as drug use, sexual health, self-harm and suicidality - are asked directly of patients at an appropriate age by clinicians during their initial appointments and responses are later entered into LimeSurvey. Having been introduced by their clinicians, these questions are subsequently asked of patients in their online follow-up questionnaires.

Parent, patient and in-clinic questionnaire responses (and scored summary data where relevant) are uploaded to patients' electronic medical record (EMR) and the RCHGS Clinical Database (DRN #DB089), and are thus available to their treating team to help guide assessment and treatment. For those who consent to being part of Trans20 following discharge from the RCHGS, follow-up questionnaires are administered via LimeSurvey and stored in the RCHGS Clinical Database.

Data from this study are stored securely on RCH servers in password-protected files that can only be accessed by study personnel. Data will be stored for 7 years post-study closure, or until the youngest participant turns 25 years old, and will then be securely destroyed. Data will be stored in a re-identifiable format, with participants given a unique, re-identifiable code that maps to identifying information, including hospital record number.

### **Measures**

Trans20 questionnaire measures were selected to provide information relevant to the assessment and treatment of GD and related co-morbidities. Measures span multiple domains including

1  
2  
3 gender, mental health, education, quality of life, parental wellbeing, family functioning, as well as  
4 their experience of care at RCHGS. Where possible, measures with strong psychometric properties  
5 and good reliability and validity were chosen. Some measures are appropriate only for specific age  
6 groups or birth-assigned sex, and the online questionnaires are tailored accordingly. A full list of  
7 Trans20 questionnaire measures is provided in Table 1, and each measure – grouped by domain -  
8 is described in further detail below.  
9

### 10 11 *Demographics and past history* 12

13 Standard demographic data and information related to the young person's medical and  
14 developmental history are routinely collected in the questionnaires. These items were developed  
15 by the study investigators; some demographic questions relating to English proficiency,  
16 Indigenous status and religious affiliation were based on standards recommended by the Australian  
17 Bureau of Statistics (ABS) (27). From age 18 years, individuals are asked questions about  
18 education and employment based on ABS Census questions (28).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Measures used in Trans20 in parent, patient and in-clinic questionnaires.

	Construct	Instrument	Reference	Parent Q'aire	Patient Q'aire	In-clinic Q'aire	Age range****
<b>Demographics &amp; History</b>							
	Demographics	Introducing you	(27, 28) T20 PT	√	√		Parent report 3-18 Patient report 3-18+
	Medical history	Medical and developmental history	T20 PT	√	√		Parent report 3-18 Patient report 18+
<b>Gender</b>							
	Gender identity and supports	About your gender – Gender Slider	T20 PT		√		3-18+
	Social transitioning	About socially transitioning	T20 PT	√	√		Parent report: 0-7 Patient report: 8-18+
	Voice	About your voice	(29, 30)		√		12-18+
	Gender role behaviours & gender identity	Gender Identity Questionnaire	(31)	√			3-12
	Gender dysphoria	Single item measuring recent gender-related distress	T20 PT		√		3-18+
	Gender dysphoria: gender preoccupation & gender stability	Gender Preoccupation and Stability Questionnaire	(32)		√		11-18+
	Body image	Body Image Scale	(33)		√	√	12-18+
	Chest dysphoria	Chest Dysphoria Scale	(34)		√		12-18+
	Hormone treatment experiences**	Medical intervention treatment effects and satisfaction. Tanner's Sexual Maturation Scale	T20 PT (35-37)		√		For those reporting that they have started puberty suppression or gender affirming hormones
<b>Mental Health</b>							
	Internalizing and externalizing behavior	Youth Self Report	(38)		√		11-18
		Preschool Child Behavior Checklist	(39)	√			1.5-5
		School-age Child Behavior Checklist	(38)	√			6-18
	Anxiety symptomatology	Spence Children's Anxiety Scale –Preschool	(40)	√			3-5
		Spence Children's Anxiety Scale -Parent report	(41)	√			6-18
		Spence Children's Anxiety Scale - Self report	(42-44)		√		7-18
	Eating disorders	Branched Eating disorder Test	(45)		√		12-18+
	Depressive symptomatology	Short Moods and Feelings Questionnaire	(46)	√	√		Parent report: 3-18 Patient report: 7-18+
	Depression, anxiety and stress	DASS-21	(47)		√		Patient report: 18+
	Social phobia	Social Phobia Scale	(48)		√		18+
	Resilience: pride and connectedness	The Gender Minority Stress and Resilience Measure	(49)		√		Patient report: 12+
	Resilience	The Brief Resilience Scale	(50)		√		Patient report: 8+
	Self-harm	Self harm questions based on Hawton et al (2002)	(51)		√	√	12-18+
	Suicidality	Columbia-Suicide Severity Rating Scale	(52)		√	√	12-18+
	Autism spectrum disorder*	Social Responsiveness Scale 2: School-age form	(53)	√			4-18

<b>School Functioning</b>							
	School attendance	About school (school type, attendance)***	(54)	√	√		Parent report: 3-18 Patient report 18+
	Academic performance	School-age Child Behavior Checklist	(38)	√			6-18
	School connectedness	Psychological Sense of School Membership Survey	(55)		√		12-18
<b>Bullying &amp; Discrimination</b>							
	Bullying	Gatehouse Bullying Scale	(56)		√		8-18
	Discrimination	Adapted from the Victorian Population Health Survey	(57)	√			18+
<b>Family Functioning</b>							
	Family functioning	Family Assessment Device -General Functioning scale	(58, 59)	√	√		Parent report: 3-18 Patient report: 12-18+
<b>Quality of Life</b>							
	Quality of life (patient)	Child Health Utility 9D	(60, 61)	√	√		Parent report: 3-5 Patient report: 6-18+
		The Assessment of Quality of Life (AQoL) - 4D	(62, 63)		√		18+
	Parental quality of life	The Assessment of Quality of Life (AQoL) - 4D	(62, 63)	√			3-18
<b>Drug use and Sexual Health</b>							
	Health risk behaviors	Tobacco, alcohol and drug use	(64-67)		√	√	12-18+
	Sexuality	Attraction and relationship questions. Adapted from the Victorian Population Health Survey	T20 PT (57)		√	√	12-18+
<b>Clinical experiences</b>							
	Discharge status**	Reasons for discharging from RCHGS	T20 PT	√	√		For those discharged from RCHGS Parent report: 3-11 Patient report: 12+
	Experiences of care**	RCHGS Experiences of care	(68-71)	√	√		Parent report: 3+ Patient report: 12+

\*only asked at initial assessment \*\*only asked at follow-up assessments; \*\*\* in young adulthood parents report on school/work; \*\*\*\* age range refers to the age of TGD youth at which questionnaires are asked of either the TGD youth and/or their parent; T20 PT = Trans20 project team devised questions; Q'aire = Questionnaire.

## Gender

Different aspects of gender identity are assessed using various complementary tools including the Gender Identity Questionnaire (31), Gender Preoccupation and Stability Questionnaire (32) and the Gender Slider. The Gender Slider, developed by the Trans20 project team in consultation with the RCHGS, is a visual analogue scale to help patients describe their gender identity. This tool consists of two continuous scales, male and female, where individuals move the slider on each scale to reflect their gender identity, from 'not at all' to 'entirely'. The Body Image Scale (33) provides information on body dissatisfaction. An item developed by the Trans20 team is used to measure extent of GD. The Social Transition Questionnaire (developed by the Trans20 team) assesses the extent to which an individual has socially transitioned. The Gender Voice Questionnaire (adapted from the Transsexual Voice Questionnaire (29, 30)) and the Chest Dysphoria Scale (administered to birth-assigned females) (34) provide information on voice dysphoria and chest dysphoria respectively. In combination, these tools enable the examination of shifts in gender identity, expression and dysphoria over time. Additional questions devised by

1  
2  
3 the project team about the effects of hormonal treatment are asked of those who have been treated  
4 with hormones.  
5

### 6 *Mental health*

7  
8  
9 Mental health is assessed longitudinally using well-validated measures chosen for their common  
10 use in this population (7, 13, 72). The Child Behaviour Checklist (CBCL) and Youth Self Report  
11 (38, 39) assess behavioural and emotional problems across broad domains including:  
12 anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thought problems,  
13 attention problems, rule-breaking behaviour, and aggressive behaviour. The Short Mood and  
14 Feelings Questionnaire (46) and Spence Children's Anxiety Scale (40-44) focus on depressive and  
15 anxiety symptomatology respectively. In young adulthood, the DASS-21 (47) is used to measure  
16 depression, anxiety and stress while social phobia is measured using the Social Phobia Scale (48).  
17 The Gender Minority Stress and Resilience Measure (community connectedness and pride scales)  
18 (49) and the Brief Resilience Scale (50) measure resilience. Assessment of self-harm is based on  
19 an established self-harm questionnaire (51), and the Columbia Suicide Severity Rating Scale (52)  
20 assesses suicidality. A modified version of the Branched Eating Disorders Test (45) is  
21 administered to assess disordered eating. Given the frequent co-occurrence of autism in gender  
22 diverse individuals (73), the Social Responsiveness Scale-2 (53) is used to screen for features of  
23 autism at the initial assessment.  
24  
25

### 26 *Education/school functioning*

27  
28  
29 Trans20 examines a range of educational outcomes over time. Academic achievement is measured  
30 using relevant questions within the CBCL (38, 39). School connectedness is assessed using the  
31 Psychological Sense of School Membership survey (55). School absenteeism is determined using  
32 modified questions from the Longitudinal Study of Australian Children (54). Finally, bullying is  
33 evaluated using the Gatehouse Bullying Scale (56) and supplemented with specific items inquiring  
34 about cyberbullying. Young adults are asked about experiences of discrimination based on  
35 questions from the Victorian Population Health Survey (57).  
36  
37  
38

### 39 *Quality of life and family functioning*

40  
41  
42 The Child Health Utility 9D (CHU 9D) (60, 61) and the Assessment of Quality of Life Instrument  
43 (AQoL-4D) (62, 63) are administered to determine how GD and its associated difficulties impact  
44 on child and parental quality of life respectively. These tools are generic quality of life measures  
45 used frequently in health economic assessments of disease impact. Australian population-based  
46 norms and utility weights exist for the AQoL-4D and CHU-9D respectively (74, 75). Family  
47 functioning is measured using the General Functioning 12-item subscale of The McMaster Family  
48 Assessment Device (58, 59).  
49

### 50 *Drug use and sexual health*

51  
52  
53 Adolescents and young adults are asked about current and lifetime alcohol, cigarette and illegal  
54 drug use, using questions adapted from the CTC survey (64-66) and the Childhood to Adolescence  
55 Transition Study (67), while sexual health information (including attraction, relationship status,  
56  
57  
58  
59

current sexual activity) is gathered via items developed by the Trans20 team and items based on the Victorian Population Health Survey (57).

### *Experiences of care*

All young people (aged 12 and older) and parents are asked about experiences of care at the RCHGS, using a questionnaire adapted from those in use at adult gender services in the US, UK, and Australia (68-71). Following discharge from the RCHGS, participants are asked the reason for discharge.

### *Physiology*

To determine the physical effects of puberty blockers and gender affirming hormones, RCHGS clinicians routinely monitor a variety of physiological parameters, including height, weight, body mass index, blood pressure, bone mineral density, luteinising hormone, follicle stimulating hormone, testosterone, oestrogen, liver function, haemoglobin, serum cholesterol, and haemoglobin A1c at regular intervals consistent with the Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescent (13). These data are stored within the EMR (for current patients) and can be directly extracted to facilitate analysis. For those who no longer attend the RCHGS, this information will be sought from patients' current treating clinician.

### **Sample size**

In the first 24 months of Trans20, 397 young people were considered eligible for involvement in Trans20. Assuming similar rates for the final 12 months of the three-year enrolment period, it is expected that the total sample will comprise approximately 600 patients. Taking this into consideration, the starting sample size is large enough to estimate with 90% power a minimum difference of 6% between two proportions or a minimum difference of .3 standard deviation between two means of two equal size groups. The statistical power may not be the same for unequal or subgroup analysis.

To estimate attrition, the number of questionnaires completed before an MDAC (or 12 months post FASST) were examined relative to those who had completed questionnaires before their FASST appointment across the first 24 months of Trans20, resulting in a retention rate of 83%. Based on these figures, it is anticipated that 498 young people will continue completing questionnaires post the three-year recruitment period.

### **Data analysis plan**

Relevant clinical outcomes (gender dysphoria, mental health, physical health, schooling, family functioning and quality of life) will be described using appropriate univariate statistics and by subgroups such as gender identity, birth-assigned sex and treatment status using bivariate statistics. Multivariate models such as linear regression or logistic regression will be used for continuous or bivariate measures respectively to explore the relationship between physiological and clinical

1  
2  
3 outcomes with gender identity adjusting for covariates. Appropriate statistical methods will be  
4 applied to analyse the repeated measures of factors over time and their effect on the outcomes.  
5

### 6 7 **Patient and public involvement**

8  
9 The RCHGS Consumer Advisory Group comprises children, adolescents and young adults who  
10 identify as TGD, families of those who identify as TGD, as well as representatives from  
11 organizations that work with or support the trans community. The RCHGS Consumer Advisory  
12 Group was consulted about the Trans20 proposal and provided input into the instruments used in  
13 Trans20 and the preferred methods of data collection. The Consumer Advisory Group will  
14 continue to be consulted to ensure that this research is conducted in a way that best suits the needs  
15 of the trans, gender diverse and non-binary community.  
16  
17

### 18 **ETHICS AND DISSEMINATION**

19  
20 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
21 the conduct of this study (#36323).  
22

23  
24 Findings from Trans20 will have translational impact by informing future treatment guidelines and  
25 gender affirming healthcare practices. It is expected that findings from the Trans20 study will be  
26 presented at conferences and published in peer reviewed journals.  
27

### 28 29 **DISCUSSION**

30  
31 Providing optimal clinical care for TGD young people is critical, but there is a lack of robust  
32 research data to inform clinical practice in this emerging field. The Trans20 study has been  
33 established to examine biopsychosocial outcomes of TGD individuals attending a large,  
34 multidisciplinary paediatric gender service. The majority of data for Trans20 are collected  
35 prospectively as part of routine clinical care to assist clinicians in providing patient care, and  
36 simultaneously offer an opportunity to address important research questions in the field of  
37 transgender child and adolescent health.  
38  
39

40  
41 Several features of Trans20 are worth highlighting. First, the longitudinal nature of the study,  
42 spanning childhood, adolescence and young adulthood will allow a number of critical questions to  
43 be addressed. The answers to these will shed light on trajectories of gender identity development  
44 in early life, risk and protective factors related to health outcomes, and the safety and effectiveness  
45 of psychosocial and hormonal interventions. Secondly, the collected data has significant breadth  
46 and depth, providing detailed information not only on gender identity, transition, dysphoria and  
47 gender-related healthcare, but also mental health, physical health, education, quality of life and  
48 family functioning, which will allow for a comprehensive range of outcomes to be examined.  
49 Thirdly, study participants are all from a single paediatric gender service that employs a consistent  
50 assessment and treatment approach and, in this way, Trans20 avoids some of the difficulties  
51 inherent in studies that recruit across multiple sites where treatment approaches may vary (25).  
52  
53

54  
55 Similar to other cohort studies, the issue of attrition should be considered in light of its potential  
56 to impact the generalizability and power of the study. Notwithstanding this, as the initial enrolment  
57  
58  
59

1  
2  
3 into Trans20 includes all patients attending the RCHGS who complete questionnaires, there is less  
4 likelihood of selection bias occurring as part of study recruitment. Furthermore, it is not ethically  
5 possible to incorporate an untreated control group in the Trans20 study design. This will limit the  
6 potential to draw direct conclusions about the effectiveness of interventions but, where possible,  
7 measures with population-based data are used in Trans20 to compare outcomes of TGD youth with  
8 those of the general population.  
9

10  
11 In conclusion, referrals of TGD children and adolescents for medical care have been increasing  
12 across the Western world, and the current demand for transgender health services may be just the  
13 tip of the iceberg. Looking ahead, it will be paramount to fill existing knowledge gaps and  
14 determine empirically how best to manage the care of TGD young people. In this regard, the  
15 Trans20 study will provide critical information on the natural history of gender diversity, the  
16 benefits and risks of current clinical pathways, identify opportunities for targeted intervention and  
17 ultimately help to improve care for this vulnerable population.  
18  
19  
20  
21

## 22 REFERENCES

- 23 1. Heard J, Morris A, Kirouac N, et al. Gender dysphoria assessment and action for youth:  
24 Review of health care services and experiences of trans youth in Manitoba. *Paediatr Child Health*.  
25 2017;23(3):179-84.
- 26 2. The Tavistock and Portman NHS Foundation Trust. GIDS referrals increase in 2017/18  
27 2018 [Available from: <http://gids.nhs.uk/news-events/2018-05-16/gids-referrals-increase-201718>.  
28
- 29 3. Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender  
30 identity disorder referred to a pediatric medical center. *Pediatrics*. 2012:418-25.
- 31 4. Telfer M, Tollit M, Feldman D. Transformation of health-care and legal systems for the  
32 transgender population: The need for change in Australia. *J Paediatr Child Health*.  
33 2015;51(11):1051-3.
- 34 5. Meerwijk EL, Sevelius JM. Transgender population size in the United States: A meta-  
35 regression of population-based probability samples. *Am J Public Health*. 2017;107(2):e1-e8.
- 36 6. Goodman M, Adams N, Cornell T, et al. Size and distribution of transgender and gender  
37 nonconforming populations: A narrative review. *Endocrinol Metab Clin North Am*.  
38 2019;48(2):303-21.
- 39 7. Strauss P, Cook A, Winter S, et al. *Trans Pathways: The Mental Health Experiences and*  
40 *Care Pathways of Trans Young People. Summary of Results.* Perth, Australia: Telethon Kids  
41 Institute; 2017.
- 42 8. Earnshaw VA, Bogart LM, Poteat VP, et al. Bullying among lesbian, gay, bisexual, and  
43 transgender youth. *Pediatr Clin North Am*. 2016;63(6):999-1010.
- 44 9. Huffaker L, Kwon P. A comprehensive approach to sexual and transgender prejudice. *J*  
45 *Gay Lesbian Soc Serv*. 2016;28(3):195-213.
- 46 10. Winter S, Diamond M, Green J, et al. Transgender people: Health at the margins of society.  
47 *The Lancet*. 2016;388(10042):390-400.
- 48 11. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual,  
49 transgender, and gender-nonconforming people, version 7. *Int J Transgend*. 2012;13(4):165-232.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



12. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2017;102(11):3869-903.
13. Telfer MM, Tollit MA, Pace CC, et al. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. *Med J Aust.* 2018;209(3):132-6.
14. Marinkovic M, Newfield RS. Chest reconstructive surgeries in transmasculine youth: Experience from one pediatric center. *Int J Transgend.* 2017;18(4):376-81.
15. Milrod C, Karasic DH. Age is just a number: WPATH-affiliated surgeons' experiences and attitudes toward vaginoplasty in transgender females under 18 years of age in the United States. *J Sex Med.* 2017;14(4):624-34.
16. Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms -- Meeting the health needs of transgender people. *N Engl J Med.* 2016;375(2):101-3.
17. Chew D, Anderson J, Williams K, et al. Hormonal treatment in young people with gender dysphoria: A systematic review. *Pediatrics.* 2018;141(4).
18. Ehrensaft D. Raising girlyboys: A parent's perspective. *Stud Gen Sex.* 2007;8(3):269-302.
19. Temple Newhook J, Pyne J, Winters K, et al. A critical commentary on follow-up studies and "desistance" theories about transgender and gender-nonconforming children. *Int J Transgend.* 2018:1-13.
20. Drummond KD, Bradley SJ, Peterson-Badali M, et al. A follow-up study of girls with gender identity disorder. *Dev Psychol.* 2008;44(1):34.
21. Steensma TD, Biemond R, de Boer F, et al. Desisting and persisting gender dysphoria after childhood: A qualitative follow-up study. *Clin Child Psychol Psychiatry.* 2011;16(4):499-516.
22. Steensma TD, McGuire JK, Kreukels BP, et al. Factors associated with desistance and persistence of childhood gender dysphoria: a quantitative follow-up study. *J Am Acad Child Adolesc Psychiatry.* 2013;52(6):582-90.
23. Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. *J Am Acad Child Adolesc Psychiatry.* 2008;47(12):1413-23.
24. de Vries A, McGuire J, Steensma T, et al. Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics.* 2014;134:696-704.
25. Reardon S. Largest ever study of transgender teenagers set to kick off. *Nature News.* 2016;531(7596):560.
26. Limesurvey GmbH. LimeSurvey: An Open Source survey tool. Hamburg, Germany: LimeSurvey GmbH.
27. McLennan W. Standards for Statistics on Cultural and Language Diversity. Canberra: Australian Bureau of Statistics; 1999.
28. Australian Bureau of Statistics. Census Household Form 2016. Available from: [http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/\\$FILE/2016%20Census%20Sample%20Household%20Form.pdf](http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/$FILE/2016%20Census%20Sample%20Household%20Form.pdf).
29. Dacakis G, Davies S, Oates JM, et al. Development and preliminary evaluation of the transsexual voice questionnaire for male-to-female transsexuals. *J Voice.* 2013;27(3):312-20.
30. Davies SM, Johnston JR. Exploring the validity of the transsexual voice questionnaire for male-to-female transsexuals. *Canadian Journal of Speech-Language Pathology and Audiology* 2015;39(1):40-51.
31. Johnson LL, Bradley SJ, Birkenfeld-Adams AS, et al. A parent-report gender identity questionnaire for children. *Arch Sex Behav.* 2004;33(2):105-16.

32. Hakeem A, Črnčec R, Asghari-Fard M, et al. Development and validation of a measure for assessing gender dysphoria in adults: The Gender Preoccupation and Stability Questionnaire. *Int J Transgend*. 2016;17(3-4):131-40.
33. Lindgren TW, Pauly IB. A body image scale for evaluating transsexuals. *Arch Sex Behav*. 1975;4(6):639-56.
34. Olson-Kennedy J, Warus J, Okonta V, et al. Chest reconstruction and chest dysphoria in transmasculine minors and young adults: Comparisons of nonsurgical and postsurgical cohorts. *JAMA Pediatr*. 2018;172(5):431-6.
35. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. *Arch Dis Child*. 1969;44(235):291.
36. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch Dis Child*. 1970;45(239):13-23.
37. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. *J Youth Adolesc*. 1980;9(3):271-80.
38. Achenbach T, Rescorla LA. *Manual for the ASEBA School-Age Forms & Profiles*. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
39. Achenbach T, Rescorla LA. *Manual for the ASEBA Preschool Forms & Profiles*. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
40. Edwards SL, Rapee RM, Kennedy SJ, et al. The assessment of anxiety symptoms in preschool-aged children: The revised preschool anxiety scale. *J Clin Child Adolesc Psychol*. 2010;39(3):400-9.
41. Nauta MH, Scholing A, Rapee RM, et al. A parent-report measure of children's anxiety: Psychometric properties and comparison with child-report in a clinic and normal sample. *Behav Res Ther*. 2004;42(7):813-39.
42. Spence SH. A measure of anxiety symptoms among children. *Behav Res Ther*. 1998;36(5):545-66.
43. Spence SH. Structure of anxiety symptoms among children: A confirmatory factor-analytic study. *J Abnorm Psychol*. 1997;106(2):280.
44. Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents. *J Anxiety Disord*. 2003;17(6):605-25.
45. Selzer R, Hamill C, Bowes G, et al. The branched eating disorders test: Validity in a nonclinical population. *Int J Eat Disord*. 1996;20(1):57-64.
46. Angold A, Costello EJ, Messer SC, et al. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. *Int J Methods Psychiatr Res*. 1995.
47. Lovibond SH, Lovibond PF. *Manual for the Depression Anxiety Stress Scales*. (2nd Ed.). Sydney: Psychology Foundation; 1995.
48. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behav Res Ther*. 1998;36(4):455-70.
49. Testa RJ, Habarth J, Peta J, et al. Development of the gender minority stress and resilience measure. *Psychol Sex Orientat Gend Divers*. 2015;2(1):65.
50. Smith BW, Dalen J, Wiggins K, et al. The brief resilience scale: Assessing the ability to bounce back. *Int J Behav Med*. 2008;15(3):194-200.
51. Hawton K, Rodham K, Evans E, et al. Deliberate self harm in adolescents: Self report survey in schools in England. *BMJ*. 2002;325(7374):1207-11.

- 1
- 2
- 3
- 4 52. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: Initial
- 5 validity and internal consistency findings from three multisite studies with adolescents and adults.
- 6 *Am J Psychiatry*. 2011;168(12):1266-77.
- 7 53. Constantino J, Gruber C. *The Social Responsiveness Scale Manual, Second Edition (SRS-*
- 8 *2)*. Los Angeles, CA: Western Psychological Services.; 2012.
- 9 54. Daraganova G. Is it OK to be away? School attendance in the primary school years. *The*
- 10 *Longitudinal Study of Australian Children Annual Statistical Report: Australian Institute of*
- 11 *Family Studies*; 2012.
- 12 55. Goodenow C. The psychological sense of school membership among adolescents: Scale
- 13 development and educational correlates. *Psychol Sch*. 1993;30(1):79-90.
- 14 56. Bond L, Wolfe S, Tollit M, et al. A comparison of the Gatehouse Bullying Scale and the
- 15 Peer Relations Questionnaire for students in secondary school. *J Sch Health*. 2007;77(2):75-9.
- 16 57. Victorian Agency for Health Information. *Victorian Population Health Survey 2017*.
- 17 Melbourne: VAHI; 2019.
- 18 58. Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. *J Marital*
- 19 *Fam Ther*. 1983;9(2):171-80.
- 20 59. Miller IW, Epstein NB, Bishop DS, et al. The McMaster family assessment device:
- 21 reliability and validity. *J Marital Fam Ther*. 1985;11(4):345-56.
- 22 60. Stevens K. Assessing the performance of a new generic measure of health-related quality
- 23 of life for children and refining it for use in health state valuation. *Appl Health Econ Health Policy*.
- 24 2011;9(3):157-69.
- 25 61. Stevens K. Valuation of the child health utility 9D index. *Pharmacoeconomics*.
- 26 2012;30(8):729-47.
- 27 62. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL)
- 28 instrument: A psychometric measure of health-related quality of life. *Quality of Life Research*.
- 29 1999;8(3):209-24.
- 30 63. Richardson J, Hawthorne G. The Australian quality of life (AQoL) instrument:
- 31 Psychometric properties of the descriptive system and initial validation. *Australian Studies in*
- 32 *Health Service Administration*. 1998;85:315-42.
- 33 64. Pollard JA, Hawkins JD, Arthur MW. Risk and protection: Are both necessary to
- 34 understand diverse behavioral outcomes in adolescence? *Soc Work Res*. 1999;23(3):145-58.
- 35 65. Glaser RR, Horn MLV, Arthur MW, et al. Measurement properties of the Communities
- 36 That Care® Youth Survey across demographic groups. *J Quant Criminol*. 2005;21(1):73-102.
- 37 66. Arthur MW, Hawkins JD, Pollard JA, et al. Measuring risk and protective factors for use,
- 38 delinquency, and other adolescent problem behaviors: The Communities That Care Youth Survey.
- 39 *Eval Rev*. 2002;26(6):575-601.
- 40 67. Mundy LK, Simmons JG, Allen NB, et al. Study protocol: The childhood to adolescence
- 41 transition study (CATS). *BMC Pediatr*. 2013;13(1):160.
- 42 68. Bockting W, Robinson B, Benner A, et al. Patient satisfaction with transgender health
- 43 services. *J Sex Marital Ther*. 2004;30(4):277-94.
- 44 69. Davies A, Bouman WP, Richards C, et al. Patient satisfaction with gender identity clinic
- 45 services in the United Kingdom. *Sex Relation Ther*. 2013;28(4):400-18.
- 46 70. Erasmus J, Bagga H, Harte F. Assessing patient satisfaction with a multidisciplinary gender
- 47 dysphoria clinic in Melbourne. *Australas Psychiatry*. 2015;23(2):158-62.
- 48 71. Wylie KR, Fitter J, Bragg A. The experience of service users with regard to satisfaction
- 49 with clinical services. *Sex Relation Ther*. 2009;24(2):163-74.
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 72. Clark T, Lucassen M, Bullen P, et al. The health and well-being of transgender high school  
4 students: Results from the New Zealand adolescent health survey (Youth'12). *J Adolesc Health*.  
5 2014;55:93-9.  
6  
7 73. Van Der Miesen AI, Hurley H, De Vries AL. Gender dysphoria and autism spectrum  
8 disorder: A narrative review. *Int Rev Psychiatry*. 2016;28(1):70-80.  
9  
10 74. Hawthorne G, Korn S, Richardson J. Population norms for the AQoL derived from the  
11 2007 Australian National Survey of Mental Health and Wellbeing. *Aust N Z J Public Health*.  
12 2013;37(1):7-16.  
13  
14 75. Furber G, Segal L. The validity of the Child Health Utility instrument (CHU9D) as a  
15 routine outcome measure for use in child and adolescent mental health services. *Health Qual Life*  
16 *Outcomes*. 2015;13(1):1.  
17  
18

### 19 **AUTHORS' CONTRIBUTIONS**

20  
21 KP, MAT, MMT and CP conceptualized the design of the study. MH devised the analysis plan.  
22 JB, CC, and NF helped to implement the study. MAT drafted the manuscript. All authors reviewed  
23 and edited the manuscript and approved the final manuscript.  
24  
25

### 26 **FUNDING STATEMENT**

27  
28  
29 The Trans20 study is supported by the RCH Foundation.  
30

### 31 **COMPETING INTERESTS STATEMENT**

32  
33 The authors have no conflicts of interest to declare.  
34

### 35 **WORD COUNT**

36  
37 Abstract: 299



38  
39 Main text (excluding table): 3836  
40

### 41 **ACKNOWLEDGEMENTS**

42  
43 We would like to acknowledge Associate Professor Sam Winter, Dr Riki Lane, Associate  
44 Professor Ruth McNair, Associate Professor Cathrine Mihalopoulos, Professor David Coghill, as  
45 well as the RCHGS team for their intellectual input into the Trans20 study design. We would also  
46 like to thank the RCHGS Consumer Advisory Group for providing feedback about the Trans20  
47 proposal and for providing input into the instruments used in Trans20 and the preferred methods  
48 of data collection.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Legend



1  
2  
3 **Figure 1.** Clinical pathway at the RCHGS and integrated questionnaire administration

4 Note: \*Indicates data collection timepoint for Trans20;  $\phi$  Following initial attendance at MDAC, questionnaires are repeated on  
5 an annual basis  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

## What are the health outcomes of trans and gender diverse young people in Australia? Study protocol for the Trans20 longitudinal cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032151.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Aug-2019
Complete List of Authors:	Tollit, Michelle; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Pace, Carmen; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Telfer , Michelle ; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Hoq, Monsurul ; Murdoch Children's Research Institute, Clinical Epidemiology and Biostatistics Unit Bryson, Janet ; Murdoch Childrens Research Institute Fulkoski, Nicholas ; Murdoch Childrens Research Institute Cooper, Charlie; Murdoch Childrens Research Institute Pang, Ken; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Health services research, Paediatrics
Keywords:	Sexual and gender disorders < PSYCHIATRY, PAEDIATRICS, MENTAL HEALTH

SCHOLARONE™  
Manuscripts

# What are the health outcomes of trans and gender diverse young people in Australia? Study protocol for the Trans20 longitudinal cohort study

**Authors:** Michelle A Tollit<sup>1,2,3</sup>, Carmen C Pace<sup>1,2,4</sup>, Michelle M Telfer<sup>1,2,4</sup>, Monsurul Hoq<sup>1</sup>, Janet Bryson<sup>1</sup>, Nicholas Fulkoski<sup>1</sup>, Charlie Cooper<sup>1</sup>, Ken Pang<sup>1,2,4,5,6</sup>

**Affiliations:**

1. Murdoch Children's Research Institute, Melbourne, Victoria, Australia
2. The Royal Children's Hospital, Department of Adolescent Medicine, Melbourne, Victoria, Australia
3. Melbourne Graduate School of Education, The University of Melbourne, Parkville, Victoria, Australia
4. Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
5. Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
6. The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

## To whom correspondence should be addressed:

Dr Michelle Tollit  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [michelle.tollit@mcri.edu.au](mailto:michelle.tollit@mcri.edu.au)  
Ph: +61 3 9345 6903

Dr Ken Pang  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [ken.pang@mcri.edu.au](mailto:ken.pang@mcri.edu.au)  
Ph: +61 3 9345 5986



## ABSTRACT

Introduction: Being transgender is frequently accompanied by gender dysphoria, which often co-exists with mental health concerns. Increased referrals of transgender and gender diverse (TGD) youth to gender clinics have been observed in many countries. Nevertheless, there is limited empirical data on the presentation and outcomes of these patients, and there is an urgent need for more evidence to ensure optimal medical and psychosocial interventions. Here we describe Trans20, a longitudinal study of TGD patients attending a multidisciplinary paediatric gender service in Melbourne, Australia. Trans20 aims to understand the demographic and clinical characteristics of these patients, to document the natural history of gender diversity presenting in childhood, and to investigate long-term outcomes for those receiving interventions.

Methods and analysis: Trans20 is a prospective cohort study based on children and adolescents first seen at the Royal Children's Hospital Gender Service (RCHGS) between February 2017 and February 2020. Current estimates indicate the final sample size will be approximately 600. Patients and their parents complete online questionnaires prior to the first appointment with RCHGS and regularly thereafter as part of routine clinical care. Upon discharge from RCHGS patients are invited to continue undertaking questionnaires biennially. In this way, a naturally forming cohort study has been created. The primary outcomes include gender dysphoria, physical and mental health, schooling, family functioning and quality of life. Subgroup analyses based on factors such as gender identity, birth-assigned sex and treatment received will be performed using bivariate and multivariate modelling as appropriate, and relevant statistical methods will be applied for the repeated measures over time.

Ethics and dissemination: The Royal Children's Hospital Human Research Ethics Committee approved this study (#36323). Findings from Trans20 will have translational impact by informing future treatment guidelines and gender affirming healthcare practices, and will be disseminated through conferences and peer reviewed journals.

### Strengths and limitations of this study

- Multiple domains including gender, mental health, physical health, schooling, family functioning and quality of life will be prospectively documented in a large cohort of TGD children and adolescents.
- Trans20 will represent one of the largest and most comprehensive longitudinal studies of TGD young people in the world, with potential to make a significant contribution to better understanding and improving the health of TGD children and adolescents globally.
- The long term follow-up of pre-pubescent children will allow examination of the natural history of gender diversity from an early age in a clinically referred population, enabling clinicians to provide accurate prognostic information to patients and families, and therefore assist decision-making around social and legal transition for TGD young people.
- Due to ethical reasons, it is not possible to incorporate an untreated control group in the Trans20 study design; this will limit the potential to draw direct conclusions about the effectiveness of interventions but, where possible, measures with population-based data are used in Trans20 to compare outcomes of TGD youth with those of the general population.

## INTRODUCTION

In recent times there has been an increase in the number of individuals identifying as transgender (1) and those seeking gender affirming healthcare (2). This rise may in part be related to increased social acceptance of gender diversity and the growing recognition that being transgender is part of the continuum of gender diversity. Despite these shifts in societal attitudes, being transgender is frequently accompanied by gender dysphoria (GD). GD is the distress that arises when a person's birth-assigned sex does not match their gender identity. GD experienced in childhood and adolescence can be particularly challenging as young people are navigating a range of physical, social and emotional changes during this critical developmental period. Serious psychiatric disorders are very common, with rates of self-reported depression and anxiety diagnoses in TGD young people in Australia as high as 75% and 72% respectively, and 80% reporting ever self-harming and 48% ever attempting suicide (3). Experiences of bullying, physical assault, discrimination and social exclusion are also common for transgender individuals (3-6), and these experiences are likely to contribute to poor mental health.

Accompanying the rise in reported prevalence of TGD young people has been a rapid increase in referrals to specialist gender clinics across the Western world (7-10). Many TGD children and adolescents and their families seek help from healthcare professionals requesting support, advice and gender affirming psychosocial and medical treatments. Best practice clinical guidelines (11-13) promote a multidisciplinary approach to address the complex biopsychosocial needs of this group, and treatment is ideally tailored to a young person's developmental stage and individual needs. Psychosocial support is central to assist the young person and their parents to understand and explore their gender identity and, where appropriate, help to facilitate social transition, which may involve adoption of gender-affirming hairstyles, clothing, names, and pronouns. For children and adolescents, psychological support can also be an important intervention for treating co-existing mental health issues, while helping to navigate the relational, social and personal challenges associated with their gender identity. For children who have not reached puberty – some of whom present with significant GD as young as age three – medical intervention is not warranted, but for older children and adolescents, medical interventions may serve an important role alongside psychosocial support and can take several forms. First, medications known as GnRH analogues (“puberty blockers”) can help to prevent the development of undesired physical changes during puberty, which can trigger and/or exacerbate GD. Secondly, gender affirming hormones, namely oestrogen and testosterone, can help promote physical changes congruent with the young person's gender identity. Thirdly, surgical procedures, such as chest reconstructive surgery for transmasculine individuals (“top surgery”), are performed on adolescents in some centres (14, 15), while genital surgery is generally only performed after the age of majority.

Specific healthcare for TGD children and adolescents – including the use of medical interventions – is relatively new, having commenced only in the past two decades. Consequently, there is a need for more empirical data to inform best practice in important areas such as risk and protective factors, and the long-term safety and outcomes of medical interventions (12, 16, 17). Another key area for which stronger evidence is required relates to the natural history of gender diversity. While some parents of TGD youth report noticing signs of gender diversity from as young as age two (18), not all gender diverse children develop a transgender identity. Published literature reports that 45-88% of children with gender concerns in childhood go on to identify with their birth-

1  
2  
3 assigned sex in adolescence and adulthood (19-23) indicating that only some of these children  
4 report a transgender identity when older. A number of methodological, interpretative and ethical  
5 concerns have been raised about these studies (19), and they are now thought to underestimate the  
6 persistence of TGD identities from childhood to adolescence. Given this uncertainty, there is a  
7 clear need to better understand these trajectories in order to inform and guide decision making in  
8 this area for young people and their families.  
9

10  
11 Various research groups around the world have been attempting to fill these important knowledge  
12 gaps via longitudinal cohort studies of TGD children and adolescents. The longest running of these  
13 has been based at VU University Medical Centre in the Netherlands, which pioneered the use of  
14 medical interventions for TGD youth and has provided much of the currently available empirical  
15 data in the field (24). More recently, an NIH-funded study commenced in the US and is aiming to  
16 follow 280 transgender youth over five years (25). The study is recruiting across four separate  
17 clinical sites, each of which have their own treatment protocols and practices. There is a clear need  
18 for additional international cohorts to sit alongside these established studies.  
19  
20

21  
22 This paper describes the creation of a new longitudinal study of TGD children and adolescents,  
23 known as Trans20. Following a large cohort of patients who have attended the state-wide Royal  
24 Children's Hospital Gender Service (RCHGS) in Melbourne, Australia, Trans20 is designed to  
25 synthesize prospectively-gathered clinical data collected from patients during their time with and  
26 after they leave the RCHGS. The RCHGS employs a consistent assessment and treatment approach  
27 to its trans healthcare, meaning that Trans20 is ideally placed to avoid the difficulties inherent in  
28 studies that recruit across multiple sites where treatment approaches may vary.  
29  
30

31 In the context of this background, the Trans20 study primarily aims to:  
32

- 33  
34 i) Describe the demographic and clinical characteristics of TGD young people who attend  
35 healthcare services for gender-related concerns  
36  
37 ii) Identify clinical outcomes following different types of gender-affirming interventions  
38 (both psychosocial and medical)  
39  
40 iii) Identify risk and protective factors associated with physical and mental health outcomes of  
41 TGD children and adolescents  
42  
43 iv) Characterize the natural history of TGD young people, including those who differ in their  
44 presentations.  
45

46  
47 Trans20 seeks to contribute to the evidence underpinning healthcare for TGD young people, and  
48 thus not only inform prognosis but also improve clinical management and decision making.  
49

## 50 **METHODS AND ANALYSIS**

### 51 **Study design**

52 Trans20 is a prospective, longitudinal cohort study, with a sample comprising patients aged 3-17  
53 years when first attending the RCHGS between February 2017 and February 2020. Online  
54 questionnaires are routinely administered as part of standard clinical care at RCHGS and are  
55 completed by patients and a nominated parent/primary caregiver prior to the first appointment with  
56  
57  
58  
59  
60

1  
2  
3 the service, and then at regular periods thereafter (Figure 1). Some questionnaires are also  
4 administered by clinicians during the patients' clinical consultations, and these are referred to as  
5 "in-clinic questionnaires" hereafter. Patients who leave the service are invited to continue  
6 undertaking questionnaires biennially. In this way, a naturally forming cohort study has been  
7 created, and our intention is to continue follow-up over a 20-year period.  
8  
9

## 10 **Study setting**

11  
12 This study is based at the RCHGS in Melbourne, Australia. The RCHGS provides publicly-funded  
13 assessment and gender affirming care to TGD young people throughout the state of Victoria.  
14 RCHGS staff come from a range of clinical specialties and disciplines including psychology,  
15 psychiatry, paediatrics, endocrinology, gynaecology, speech therapy and nursing. With  
16 approximately 250 new referrals each year, RCHGS is the largest multidisciplinary gender service  
17 for children and adolescents in Australia. Young people up to age 17 years who reside in Victoria  
18 and have concerns regarding their gender identity can be referred to RCHGS by their general  
19 practitioner. Patients subsequently enter the service via one of two pathways: the Under 8 clinic  
20 for those aged 7 years and below, or the First Assessment Single Session Triage (FASST) clinic  
21 for those aged 8 years and older. Patients attending the Under 8 clinic are assigned a mental health  
22 clinician for initial assessment and support, and those wishing to undertake a medical transition  
23 are later referred to a member of the paediatric team prior to onset of puberty. Patients attending  
24 the FASST clinic see a Clinical Nurse Consultant or an Adolescent Medicine fellow (doctor  
25 undergoing advanced pediatric training) for initial assessment and support; those who wish to  
26 receive further psychosocial support and/or medical intervention are subsequently seen in the  
27 Multidisciplinary Assessment Clinic (MDAC) (Figure 1). Regardless of which pathway a patient  
28 enters, they and their parents undertake an assessment which includes the completion of  
29 standardised questionnaires prior to their first appointment, and these assessments are repeated at  
30 regular (~12 monthly) intervals as patients continue to attend the service.  
31  
32  
33  
34  
35

## 36 **Participants and eligibility**

37  
38 To be eligible for inclusion in Trans20, participants need to have attended an initial appointment  
39 with the RCHGS between February 2017 - February 2020, have completed at least one of the  
40 baseline questionnaires (i.e., patient questionnaire, parent questionnaire, or in-clinic  
41 questionnaire), and speak sufficient English to complete the questionnaires. Since patients can be  
42 referred to the RCHGS at any age before 18 years, participants are expected to range in age from  
43 3-17 years at study entry. Data from the first two years of the study indicate that on the day of first  
44 appointment with the RCHGS, the large majority of patients (75.3%) were aged 12 years or older,  
45 18.6% were aged 6-11 years and 6.1% were aged 5 years or younger. Based on those meeting  
46 eligibility for involvement in Trans20 in the first two years, it is expected that the Trans20 cohort  
47 will comprise approximately 600 participants over the three-year enrolment period.  
48  
49  
50  
51

## 52 **Ethics, recruitment and consent**

53  
54 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
55 the conduct of this study (#36323). As previously outlined, questionnaires are completed by  
56  
57  
58  
59

1  
2  
3 patients and parents as part of routine clinical care at RCHGS, and this information will be  
4 analysed under a clinical audit framework. As Trans20 is designed to prospectively collect data  
5 from patients beyond their time with the RCHGS, long-term follow up of patients who leave the  
6 RCHGS requires specific consent. Consent is obtained using a multi-step procedure, from parents  
7 for those aged under 18 years, and from young people themselves once they are aged 18 years or  
8 older. At the time of undertaking assessments with the RCHGS, permission to contact patients and  
9 their families about the Trans20 study in the future is prospectively collected. Following discharge,  
10 those who have provided consent to be contacted are then invited to continue to undertake  
11 assessments. For patients who have left the service and are under 18 years, an email with parent  
12 and participant information statements as well as questionnaire links are sent to the nominated  
13 parent, who are asked to pass the relevant documentation to their child if they consent to them  
14 being involved. Patients who have left the service and are 18 years or older are sent these directly  
15 via email. Under each of these scenarios, completion of the online questionnaires provides implied  
16 consent. Consent to contact treating clinicians to obtain physical health information will also be  
17 sought for those who no longer attend the RCHGS.  
18  
19  
20

### 21 **Data collection and storage**

22  
23  
24 Parent and patient questionnaires are administered via LimeSurvey, an online, open source, survey  
25 web application (26), supported by the RCH for clinical use. Separate parent and patient  
26 questionnaire links are sent to a parent email address, and parents and patients complete the  
27 questionnaires online. Questionnaires are administered approximately one month prior to patients'  
28 initial appointment with the service, and then at approximately 12 month intervals throughout their  
29 RCHGS episode of care. Information on community supports are provided at the end of all  
30 questionnaires. Participants (who no longer attend the RCHGS) who disclose information that  
31 raises concern about a significant risk of harm will be contacted by project staff to provide  
32 additional support. This may include: discussing additional support services, encouraging the  
33 participant to contact their general practitioner and/or access existing supports and referring the  
34 participant to external supports (including mental health triaging services) where appropriate.  
35  
36  
37

38 In-clinic questionnaires – which cover topics such as drug use, sexual health, self-harm and  
39 suicidality - are asked directly of patients at an appropriate age by clinicians during their  
40 appointments and responses are later entered into LimeSurvey. Having been introduced by their  
41 clinicians, these questions are subsequently asked of patients in their online follow-up  
42 questionnaires.  
43  
44

45 Parent, patient and in-clinic questionnaire responses (and scored summary data where relevant)  
46 are uploaded to patients' electronic medical record (EMR) and the RCHGS Clinical Database  
47 (DRN #DB089). Thus, these are available to their treating team to help guide assessment and  
48 treatment. For those who consent to being part of Trans20 following discharge from the RCHGS,  
49 follow-up questionnaires are administered via LimeSurvey and stored in the RCHGS Clinical  
50 Database. For those discharged from RCHGS a \$20 gift voucher will be offered as a sign of  
51 appreciation and as reimbursement for the time spent completing the surveys.  
52  
53

54 Data from this study are stored securely on RCH servers in password-protected files that can only  
55 be accessed by study personnel. Data will be stored for 7 years post-study closure, or until the  
56  
57  
58  
59

1  
2  
3 youngest participant turns 25 years old, and will then be securely destroyed. Data will be stored  
4 in a re-identifiable format, with participants given a unique, re-identifiable code that maps to  
5 identifying information, including hospital record number.  
6  
7

## 8 **Measures**

9

10 Trans20 questionnaire measures were selected to provide information relevant to the assessment  
11 and treatment of GD and related co-morbidities. Measures span multiple domains including  
12 gender, mental health, education, quality of life, parental wellbeing, family functioning, as well as  
13 their experience of care at RCHGS. In addition to measuring core gender-related and mental health  
14 outcomes, broader indicators of health and wellbeing were also included to holistically and  
15 comprehensively assess multifaceted functioning (including at school and within the family) which  
16 may be related to gender and mental health outcomes in this group. Where possible, measures with  
17 strong psychometric properties and good reliability and validity were chosen. Some measures are  
18 appropriate only for specific age groups or birth-assigned sex, and the online questionnaires are  
19 tailored accordingly. A full list of Trans20 questionnaire measures is provided in Table 1, and each  
20 measure – grouped by domain - is described in further detail below.  
21  
22

### 23 *Demographics and past history*

24

25  
26 Standard demographic data and information related to the young person's medical and  
27 developmental history are routinely collected in the questionnaires. These items were developed  
28 by the study investigators; some demographic questions relating to English proficiency,  
29 Indigenous status and religious affiliation were based on standards recommended by the Australian  
30 Bureau of Statistics (ABS) (27). From age 18 years, individuals are asked questions about  
31 education and employment based on ABS Census questions (28).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Measures used in Trans20 in parent, patient and in-clinic questionnaires.

	Construct	Instrument	Reference	Parent Q'aire	Patient Q'aire	In-clinic Q'aire	Age range****
<b>Demographics &amp; History</b>							
	Demographics	Introducing you	(27, 28) T20 PT	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: all ages – no age restrictions
	Medical history	Medical and developmental history	T20 PT	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 18+
<b>Gender</b>							
	Gender identity and supports	About your gender – Gender Slider	T20 PT		√		All ages – no age restrictions
	Social transitioning	About socially transitioning	T20 PT	√	√		Parent report: 0-7 Patient report: 8+
	Voice	About your voice	(29, 30)		√		12+
	Gender role behaviours & gender identity	Gender Identity Questionnaire	(31)	√			<=12
	Gender dysphoria	Single item measuring recent gender-related distress	T20 PT		√		All ages – no age restrictions
	Gender dysphoria: gender preoccupation & gender stability	Gender Preoccupation and Stability Questionnaire	(32)		√		11+
	Body image	Body Image Scale	(33)		√	√	12+
	Chest dysphoria	Chest Dysphoria Scale	(34)		√		12+ (birth-assigned females)
	Hormone treatment experiences**	Medical intervention treatment effects and satisfaction. Tanner's Sexual Maturation Scale	T20 PT (35-37)		√		12+ for those reporting that they have started puberty suppression or gender affirming hormones
<b>Mental Health</b>							
	Internalizing and externalizing behavior	Youth Self Report	(38)		√		11-18
		Preschool Child Behavior Checklist	(39)	√			1.5-5
		School-age Child Behavior Checklist	(38)	√			6-18
	Anxiety symptomatology	Spence Children's Anxiety Scale –Preschool	(40)	√			3-5
		Spence Children's Anxiety Scale -Parent report	(41)	√			6-18
		Spence Children's Anxiety Scale - Self report	(42-44)		√		7-18
	Eating disorders	Branched Eating disorder Test	(45)		√		12+
	Depressive symptomatology	Short Mood and Feelings Questionnaire	(46)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS***. Patient report: 7+
	Depression, anxiety and stress	Depression Anxiety Stress Scales -21 (DASS21)	(47)		√		Patient report: 18+
	Social phobia	Social Phobia Scale	(48)		√		18+



	Resilience: pride and connectedness	The Gender Minority Stress and Resilience Measure	(49)		√		Patient report: 12+
	Resilience	The Brief Resilience Scale	(50)		√		Patient report: 8+
	Self-harm	Self-harm questions based on Hawton et al (2002)	(51)		√	√	12+
	Suicidality	Columbia-Suicide Severity Rating Scale	(52)		√	√	12+
	Autism features*	Social Responsiveness Scale 2: School-age form	(53)	√			4-18
<b>School Functioning</b>							
	School attendance	About school (school type, attendance)	(54)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 18+
	Academic performance	School-age Child Behavior Checklist	(38)	√			6-18
	School connectedness	Psychological Sense of School Membership Survey	(55)		√		12-18
<b>Bullying &amp; Discrimination</b>							
	Bullying	Gatehouse Bullying Scale	(56)		√		8-18
	Discrimination	Adapted from the Victorian Population Health Survey	(57)	√			18+
<b>Family Functioning</b>							
	Family functioning	Family Assessment Device -General Functioning scale	(58, 59)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 12+
<b>Quality of Life</b>							
	Quality of life (patient)	Child Health Utility 9D	(60, 61)	√	√		Parent report: <=5 Patient report: 6+
		The Assessment of Quality of Life (AQoL) - 4D	(62, 63)		√		18+
	Parental quality of life	The Assessment of Quality of Life (AQoL) - 4D	(62, 63)	√			All ages – no age restrictions while patient at RCHGS***
<b>Drug use and Sexual Health</b>							
	Health risk behaviors	Tobacco, alcohol and drug use	(64-67)		√	√	12+
	Sexuality	Attraction and relationship questions. Adapted from the Victorian Population Health Survey	T20 PT (57)		√	√	12+
<b>Clinical experiences</b>							
	Discharge status**	Reasons for discharging from RCHGS	T20 PT	√	√		For those discharged from RCHGS Parent report: <=11 Patient report: 12+
	Experiences of care**	RCHGS Experiences of care	(68-71)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 12+

\*only asked at initial assessment \*\*only asked at follow-up assessments; \*\*\*Not administered to parent if young person is aged 18 years (or older) and discharged from RCHGS ; \*\*\*\* age range refers to the age of TGD youth at which questionnaires are asked of either the TGD youth and/or their parent; T20 PT = Trans20 project team devised questions; Q'aire = Questionnaire.

## Gender

1  
2  
3 Different aspects of gender identity are assessed using various complementary tools including the  
4 Gender Identity Questionnaire (31), Gender Preoccupation and Stability Questionnaire (32) and  
5 the Gender Slider. The Gender Slider, developed by the Trans20 project team in consultation with  
6 the RCHGS, is a visual analogue scale to help patients describe their gender identity. This tool  
7 consists of two continuous scales, male and female, where individuals move the slider on each  
8 scale to reflect their gender identity, from 'not at all' to 'completely'. The Body Image Scale (33)  
9 provides information on body dissatisfaction. An item developed by the Trans20 team is used to  
10 measure extent of GD. The Social Transition Questionnaire (developed by the Trans20 team)  
11 assesses the extent to which an individual has socially transitioned. The Gender Voice  
12 Questionnaire (adapted from the Transsexual Voice Questionnaire (29, 30)) and the Chest  
13 Dysphoria Scale (administered to birth-assigned females) (34) provide information on voice  
14 dysphoria and chest dysphoria respectively. In combination, these tools enable the examination  
15 of shifts in gender identity, expression and dysphoria over time. Additional questions devised by  
16 the project team about the effects of hormonal treatment are asked of those who have been treated  
17 with hormones.  
18  
19  
20

### 21 *Mental health*

22  
23  
24 Mental health is assessed longitudinally using well-validated measures chosen for their common  
25 use in this population. The Child Behavior Checklist (CBCL) and Youth Self Report (38, 39)  
26 assess behavioural and emotional problems across broad domains including: anxious/depressed,  
27 withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems,  
28 rule-breaking behaviour, and aggressive behaviour. The Short Mood and Feelings Questionnaire  
29 (46) and Spence Children's Anxiety Scale (40-44) focus on depressive and anxiety  
30 symptomatology respectively. In young adulthood, the DASS21 (47) is used to measure  
31 depression, anxiety and stress while social phobia is measured using the Social Phobia Scale (48).  
32 The Gender Minority Stress and Resilience Measure (community connectedness and pride scales)  
33 (49) and the Brief Resilience Scale (50) measure resilience. Assessment of self-harm is based on  
34 an established self-harm questionnaire (51), and the Columbia-Suicide Severity Rating Scale (52)  
35 assesses suicidality. A modified version of the Branched Eating Disorders Test (45) is  
36 administered to assess disordered eating. Given the frequent co-occurrence of autism in gender  
37 diverse individuals (72), the Social Responsiveness Scale-2 (53) is used to screen for features of  
38 autism at the initial assessment.  
39  
40  
41

### 42 *Education/school functioning*

43  
44  
45 Trans20 examines a range of educational outcomes over time. Academic achievement is measured  
46 using relevant questions within the CBCL (38, 39). School connectedness is assessed using the  
47 Psychological Sense of School Membership survey (55). School absenteeism is determined using  
48 modified questions from the Longitudinal Study of Australian Children (54). Finally, bullying is  
49 evaluated using the Gatehouse Bullying Scale (56) and supplemented with specific items inquiring  
50 about cyberbullying. Young adults are asked about experiences of discrimination based on  
51 questions from the Victorian Population Health Survey (57).  
52  
53

### 54 *Quality of life and family functioning*

1  
2  
3 The Child Health Utility 9D (CHU 9D) (60, 61) and the Assessment of Quality of Life Instrument  
4 (AQoL-4D) (62, 63) are administered to determine how GD and its associated difficulties impact  
5 on child and parental quality of life respectively. These tools are generic quality of life measures  
6 used frequently in health economic assessments of disease impact. Australian population-based  
7 norms and utility weights exist for the AQoL-4D and CHU-9D respectively (73, 74). Family  
8 functioning is measured using the General Functioning 12-item subscale of The McMaster Family  
9 Assessment Device (58, 59).

### 12 *Drug use and sexual health*

14  
15 Adolescents and young adults are asked about current and lifetime alcohol, cigarette and illegal  
16 drug use, using questions adapted from the CTC survey (64-66) and the Childhood to Adolescence  
17 Transition Study (67), while sexual health information (including attraction, relationship status,  
18 current sexual activity) is gathered via items developed by the Trans20 team and items based on  
19 the Victorian Population Health Survey (57).

### 22 *Experiences of care*

24  
25 Young people (aged 12 and older) and all parents are asked about experiences of care at the  
26 RCHGS, using a questionnaire adapted from those in use at adult gender services in the US, UK,  
27 and Australia (68-71). Following discharge from the RCHGS, participants are asked the reason for  
28 discharge.

### 30 *Physiology*

32  
33 To determine the physical effects of puberty blockers and gender affirming hormones, RCHGS  
34 clinicians routinely monitor a variety of physiological parameters, including height, weight, body  
35 mass index, blood pressure, bone mineral density, luteinising hormone, follicle stimulating  
36 hormone, testosterone, oestrogen, liver function, haemoglobin, serum cholesterol, and  
37 haemoglobin A1c at regular intervals consistent with the Australian Standards of Care and  
38 Treatment Guidelines for Trans and Gender Diverse Children and Adolescents (13). These data  
39 are stored within the EMR (for current patients) and can be directly extracted to facilitate analysis.  
40 Patients on puberty blockers and gender affirming hormones are reviewed by clinicians  
41 approximately every 3-6 months, and we will routinely extract physical health information  
42 generated from these appointments from patients' medical record. For those who no longer attend  
43 the RCHGS, this information will be sought from patients' current treating clinician, at  
44 approximately the same time as their scheduled online assessments.

### 47 **Sample size**

49  
50 In the first 24 months of Trans20, 397 young people were considered eligible for involvement in  
51 Trans20. Assuming similar rates for the final 12 months of the three-year enrolment period, it is  
52 expected that the total sample will comprise approximately 600 patients. Taking this into  
53 consideration, the starting sample size is large enough to estimate with 90% power a minimum  
54 difference of 6% between two proportions or a minimum difference of .3 standard deviation  
55

1  
2  
3 between two means of two equal size groups. The statistical power may not be the same for unequal  
4 or subgroup analysis.  
5

6  
7 To estimate attrition, the number of questionnaires completed before an MDAC (or 12 months  
8 post FASST) were examined relative to those who had completed questionnaires before their  
9 FASST appointment across the first 24 months of Trans20, resulting in a retention rate of 83%.  
10 Based on these figures, it is anticipated that 498 young people will continue completing  
11 questionnaires post the three-year recruitment period.  
12

### 13 14 **Data analysis plan** 15

16 Relevant clinical outcomes (gender dysphoria, mental health, physical health, schooling, family  
17 functioning and quality of life) will be described using appropriate univariate statistics and by  
18 subgroups such as gender identity, birth-assigned sex and treatment status using bivariate statistics.  
19 Multivariate models such as linear regression or logistic regression will be used for continuous or  
20 bivariate measures respectively to explore the relationship between physiological and clinical  
21 outcomes with gender identity adjusting for covariates. Appropriate statistical methods will be  
22 applied to analyse the repeated measures of factors over time, their effect on the outcomes  
23 including missing data if necessary.  
24  
25

### 26 27 **Patient and public involvement** 28

29 The RCHGS Consumer Advisory Group comprises children, adolescents and young adults who  
30 identify as TGD, families of those who identify as TGD, as well as representatives from  
31 organizations that work with or support the trans community. The RCHGS Consumer Advisory  
32 Group was consulted about the Trans20 proposal and provided input into the instruments used in  
33 Trans20 and the preferred methods of data collection. The Consumer Advisory Group will  
34 continue to be consulted to ensure that this research is conducted in a way that best suits the needs  
35 of the trans, gender diverse and non-binary community.  
36  
37

### 38 39 **ETHICS AND DISSEMINATION** 40

41 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
42 the conduct of this study (#36323).  
43

44 Findings from Trans20 will have translational impact by informing future treatment guidelines and  
45 gender affirming healthcare practices. It is expected that findings from the Trans20 study will be  
46 presented at conferences and published in peer reviewed journals.  
47  
48

### 49 50 **DISCUSSION** 51

52 Providing optimal clinical care for TGD young people is critical, but there is a need for stronger  
53 empirical research data to inform clinical practice in this emerging field. The Trans20 study has  
54 been established to examine biopsychosocial outcomes of TGD individuals attending a large,  
55 multidisciplinary paediatric gender service. The majority of data for Trans20 are collected  
56 prospectively as part of routine clinical care to assist clinicians in providing patient care, and  
57  
58  
59  
60

1  
2  
3 simultaneously offer an opportunity to address important research questions in the field of  
4 transgender child and adolescent health.  
5

6  
7 Several features of Trans20 are worth highlighting. First, the longitudinal nature of the study,  
8 spanning childhood, adolescence and young adulthood will allow a number of critical questions to  
9 be addressed. The answers to these will shed light on trajectories of gender identity development  
10 in early life, risk and protective factors related to health outcomes, and the safety and effectiveness  
11 of psychosocial and hormonal interventions. Secondly, the collected data has significant breadth  
12 and depth, providing detailed information not only on gender identity, transition, dysphoria and  
13 gender-related healthcare, but also mental health, physical health, education, quality of life and  
14 family functioning, which will allow for a comprehensive range of outcomes to be examined.  
15 Thirdly, study participants are all from a single paediatric gender service that employs a consistent  
16 assessment and treatment approach and, in this way, Trans20 avoids some of the difficulties  
17 inherent in studies that recruit across multiple sites where treatment approaches may vary.  
18  
19

20  
21 Similar to other cohort studies, the issue of attrition should be considered in light of its potential  
22 to impact the generalizability and power of the study. Notwithstanding this, as the initial enrolment  
23 into Trans20 includes all patients attending the RCHGS who complete questionnaires, there is less  
24 likelihood of selection bias occurring as part of study recruitment. Furthermore, it is not ethically  
25 possible to incorporate an untreated control group in the Trans20 study design. This is because  
26 withholding treatment for the purposes of forming a comparison group may cause patients  
27 significant distress and therefore pose significant risk of harm to individuals. Absence of a control  
28 group will limit the potential to draw direct conclusions about the effectiveness of interventions  
29 but, where possible, measures with population-based data are used in Trans20 to compare  
30 outcomes of TGD youth with those of the general population.  
31  
32

33  
34 In conclusion, referrals of TGD children and adolescents for medical care have been increasing  
35 across the Western world, and the current demand for transgender health services may be just the  
36 tip of the iceberg. Looking ahead, it will be paramount to fill existing knowledge gaps and  
37 determine empirically how best to manage the care of TGD young people so that future best  
38 practice guidelines can be based on as much robust evidence as possible. In this regard, the Trans20  
39 study will provide critical information pertinent to clinical practice and its provision. It will provide  
40 integral information on the natural history of gender diversity, which will enable clinicians to  
41 provide accurate prognostic information to patients and families, and therefore assist decision-  
42 making around social and legal transition for TGD young people. The study will also provide  
43 important information on the benefits and risks of current clinical pathways which could be used  
44 to inform the TGD community about the long-term safety and outcomes of different forms of  
45 medical interventions available to them. Finally, the longitudinal nature of Trans20 will allow  
46 opportunities for targeted interventions to be identified, and ultimately help to improve care for  
47 this vulnerable population.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Meerwijk EL, Sevelius JM. Transgender population size in the United States: A meta-regression of population-based probability samples. *Am J Public Health*. 2017;107(2):e1-e8.
2. Goodman M, Adams N, Cornell T, et al. Size and distribution of transgender and gender nonconforming populations: A narrative review. *Endocrinol Metab Clin North Am*. 2019;48(2):303-21.
3. Strauss P, Cook A, Winter S, et al. *Trans Pathways: The Mental Health Experiences and Care Pathways of Trans Young People. Summary of Results*. Perth, Australia: Telethon Kids Institute; 2017.
4. Earnshaw VA, Bogart LM, Poteat VP, et al. Bullying among lesbian, gay, bisexual, and transgender youth. *Pediatr Clin North Am*. 2016;63(6):999-1010.
5. Huffaker L, Kwon P. A comprehensive approach to sexual and transgender prejudice. *J Gay Lesbian Soc Serv*. 2016;28(3):195-213.
6. Winter S, Diamond M, Green J, et al. Transgender people: Health at the margins of society. *The Lancet*. 2016;388(10042):390-400.
7. Heard J, Morris A, Kirouac N, et al. Gender dysphoria assessment and action for youth: Review of health care services and experiences of trans youth in Manitoba. *Paediatr Child Health*. 2017;23(3):179-84.
8. The Tavistock and Portman NHS Foundation Trust. GIDS referrals increase in 2017/18 2018 [Available from: <http://gids.nhs.uk/news-events/2018-05-16/gids-referrals-increase-201718>].
9. Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. *Pediatrics*. 2012:418-25.
10. Telfer M, Tollit M, Feldman D. Transformation of health-care and legal systems for the transgender population: The need for change in Australia. *J Paediatr Child Health*. 2015;51(11):1051-3.
11. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. *Int J Transgend*. 2012;13(4):165-232.
12. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869-903.
13. Telfer MM, Tollit MA, Pace CC, et al. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. *Med J Aust*. 2018;209(3):132-6.
14. Marinkovic M, Newfield RS. Chest reconstructive surgeries in transmasculine youth: Experience from one pediatric center. *Int J Transgend*. 2017;18(4):376-81.
15. Milrod C, Karasic DH. Age is just a number: WPATH-affiliated surgeons' experiences and attitudes toward vaginoplasty in transgender females under 18 years of age in the United States. *J Sex Med*. 2017;14(4):624-34.
16. Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms -- Meeting the health needs of transgender people. *N Engl J Med*. 2016;375(2):101-3.
17. Chew D, Anderson J, Williams K, et al. Hormonal treatment in young people with gender dysphoria: A systematic review. *Pediatrics*. 2018;141(4).
18. Ehrensaft D. Raising girlyboys: A parent's perspective. *Stud Gen Sex*. 2007;8(3):269-302.
19. Temple Newhook J, Pyne J, Winters K, et al. A critical commentary on follow-up studies and "desistance" theories about transgender and gender-nonconforming children. *Int J Transgend*. 2018:1-13.

20. Drummond KD, Bradley SJ, Peterson-Badali M, et al. A follow-up study of girls with gender identity disorder. *Dev Psychol*. 2008;44(1):34.
21. Steensma TD, Biemond R, de Boer F, et al. Desisting and persisting gender dysphoria after childhood: A qualitative follow-up study. *Clin Child Psychol Psychiatry*. 2011;16(4):499-516.
22. Steensma TD, McGuire JK, Kreukels BP, et al. Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. *J Am Acad Child Adolesc Psychiatry*. 2013;52(6):582-90.
23. Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. *J Am Acad Child Adolesc Psychiatry*. 2008;47(12):1413-23.
24. de Vries A, McGuire J, Steensma T, et al. Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics*. 2014;134:696-704.
25. Reardon S. Largest ever study of transgender teenagers set to kick off. *Nature News*. 2016;531(7596):560.
26. Limesurvey GmbH. LimeSurvey: An Open Source survey tool. Hamburg, Germany: LimeSurvey GmbH.
27. McLennan W. Standards for Statistics on Cultural and Language Diversity. Canberra: Australian Bureau of Statistics; 1999.
28. Australian Bureau of Statistics. Census Household Form 2016. Available from: [http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/\\$FILE/2016%20Census%20Sample%20Household%20Form.pdf](http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/$FILE/2016%20Census%20Sample%20Household%20Form.pdf).
29. Dacakis G, Davies S, Oates JM, et al. Development and preliminary evaluation of the transsexual voice questionnaire for male-to-female transsexuals. *J Voice*. 2013;27(3):312-20.
30. Davies SM, Johnston JR. Exploring the validity of the transsexual voice questionnaire for male-to-female transsexuals. *Canadian Journal of Speech-Language Pathology and Audiology* 2015;39(1):40-51.
31. Johnson LL, Bradley SJ, Birkenfeld-Adams AS, et al. A parent-report gender identity questionnaire for children. *Arch Sex Behav*. 2004;33(2):105-16.
32. Hakeem A, Črnčec R, Asghari-Fard M, et al. Development and validation of a measure for assessing gender dysphoria in adults: The Gender Preoccupation and Stability Questionnaire. *Int J Transgend*. 2016;17(3-4):131-40.
33. Lindgren TW, Pauly IB. A body image scale for evaluating transsexuals. *Arch Sex Behav*. 1975;4(6):639-56.
34. Olson-Kennedy J, Warus J, Okonta V, et al. Chest reconstruction and chest dysphoria in transmasculine minors and young adults: Comparisons of nonsurgical and postsurgical cohorts. *JAMA Pediatr*. 2018;172(5):431-6.
35. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. *Arch Dis Child*. 1969;44(235):291.
36. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch Dis Child*. 1970;45(239):13-23.
37. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. *J Youth Adolesc*. 1980;9(3):271-80.
38. Achenbach T, Rescorla LA. Manual for the ASEBA School-Age Forms & Profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
39. Achenbach T, Rescorla LA. Manual for the ASEBA Preschool Forms & Profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2000.

- 1
- 2
- 3
- 4 40. Edwards SL, Rapee RM, Kennedy SJ, et al. The assessment of anxiety symptoms in
- 5 preschool-aged children: The revised preschool anxiety scale. *J Clin Child Adolesc Psychol.*
- 6 2010;39(3):400-9.
- 7 41. Nauta MH, Scholing A, Rapee RM, et al. A parent-report measure of children's anxiety:
- 8 Psychometric properties and comparison with child-report in a clinic and normal sample. *Behav*
- 9 *Res Ther.* 2004;42(7):813-39.
- 10 42. Spence SH. A measure of anxiety symptoms among children. *Behav Res Ther.*
- 11 1998;36(5):545-66.
- 12 43. Spence SH. Structure of anxiety symptoms among children: A confirmatory factor-analytic
- 13 study. *J Abnorm Psychol.* 1997;106(2):280.
- 14 44. Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children's
- 15 Anxiety Scale with young adolescents. *J Anxiety Disord.* 2003;17(6):605-25.
- 16 45. Selzer R, Hamill C, Bowes G, et al. The branched eating disorders test: Validity in a
- 17 nonclinical population. *Int J Eat Disord.* 1996;20(1):57-64.
- 18 46. Angold A, Costello EJ, Messer SC, et al. Development of a short questionnaire for use in
- 19 epidemiological studies of depression in children and adolescents. *Int J Methods Psychiatr Res.*
- 20 1995.
- 21 47. Lovibond SH, Lovibond PF. *Manual for the Depression Anxiety Stress Scales.* (2nd Ed.).
- 22 Sydney: Psychology Foundation; 1995.
- 23 48. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny
- 24 fear and social interaction anxiety. *Behav Res Ther.* 1998;36(4):455-70.
- 25 49. Testa RJ, Habarth J, Peta J, et al. Development of the gender minority stress and resilience
- 26 measure. *Psychol Sex Orientat Gend Divers.* 2015;2(1):65.
- 27 50. Smith BW, Dalen J, Wiggins K, et al. The brief resilience scale: Assessing the ability to
- 28 bounce back. *Int J Behav Med.* 2008;15(3):194-200.
- 29 51. Hawton K, Rodham K, Evans E, et al. Deliberate self harm in adolescents: Self report
- 30 survey in schools in England. *BMJ.* 2002;325(7374):1207-11.
- 31 52. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: Initial
- 32 validity and internal consistency findings from three multisite studies with adolescents and adults.
- 33 *Am J Psychiatry.* 2011;168(12):1266-77.
- 34 53. Constantino J, Gruber C. *The Social Responsiveness Scale Manual, Second Edition (SRS-*
- 35 *2).* Los Angeles, CA: Western Psychological Services.; 2012.
- 36 54. Daraganova G. Is it OK to be away? School attendance in the primary school years. *The*
- 37 *Longitudinal Study of Australian Children Annual Statistical Report: Australian Institute of*
- 38 *Family Studies;* 2012.
- 39 55. Goodenow C. The psychological sense of school membership among adolescents: Scale
- 40 development and educational correlates. *Psychol Sch.* 1993;30(1):79-90.
- 41 56. Bond L, Wolfe S, Tollit M, et al. A comparison of the Gatehouse Bullying Scale and the
- 42 Peer Relations Questionnaire for students in secondary school. *J Sch Health.* 2007;77(2):75-9.
- 43 57. Victorian Agency for Health Information. *Victorian Population Health Survey 2017.*
- 44 Melbourne: VAHI; 2019.
- 45 58. Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. *J Marital*
- 46 *Fam Ther.* 1983;9(2):171-80.
- 47 59. Miller IW, Epstein NB, Bishop DS, et al. The McMaster family assessment device:
- 48 reliability and validity. *J Marital Fam Ther.* 1985;11(4):345-56.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



- 1  
2  
3 60. Stevens K. Assessing the performance of a new generic measure of health-related quality  
4 of life for children and refining it for use in health state valuation. *Appl Health Econ Health Policy*.  
5 2011;9(3):157-69.  
6  
7 61. Stevens K. Valuation of the child health utility 9D index. *Pharmacoeconomics*.  
8 2012;30(8):729-47.  
9  
10 62. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL)  
11 instrument: A psychometric measure of health-related quality of life. *Quality of Life Research*.  
12 1999;8(3):209-24.  
13  
14 63. Richardson J, Hawthorne G. The Australian quality of life (AQoL) instrument:  
15 Psychometric properties of the descriptive system and initial validation. *Australian Studies in*  
16 *Health Service Administration*. 1998;85:315-42.  
17  
18 64. Pollard JA, Hawkins JD, Arthur MW. Risk and protection: Are both necessary to  
19 understand diverse behavioral outcomes in adolescence? *Soc Work Res*. 1999;23(3):145-58.  
20  
21 65. Glaser RR, Horn MLV, Arthur MW, et al. Measurement properties of the Communities  
22 That Care® Youth Survey across demographic groups. *J Quant Criminol*. 2005;21(1):73-102.  
23  
24 66. Arthur MW, Hawkins JD, Pollard JA, et al. Measuring risk and protective factors for use,  
25 delinquency, and other adolescent problem behaviors: The Communities That Care Youth Survey.  
26 *Eval Rev*. 2002;26(6):575-601.  
27  
28 67. Mundy LK, Simmons JG, Allen NB, et al. Study protocol: The childhood to adolescence  
29 transition study (CATS). *BMC Pediatr*. 2013;13(1):160.  
30  
31 68. Bockting W, Robinson B, Benner A, et al. Patient satisfaction with transgender health  
32 services. *J Sex Marital Ther*. 2004;30(4):277-94.  
33  
34 69. Davies A, Bouman WP, Richards C, et al. Patient satisfaction with gender identity clinic  
35 services in the United Kingdom. *Sex Relation Ther*. 2013;28(4):400-18.  
36  
37 70. Erasmus J, Bagga H, Harte F. Assessing patient satisfaction with a multidisciplinary gender  
38 dysphoria clinic in Melbourne. *Australas Psychiatry*. 2015;23(2):158-62.  
39  
40 71. Wylie KR, Fitter J, Bragg A. The experience of service users with regard to satisfaction  
41 with clinical services. *Sex Relation Ther*. 2009;24(2):163-74.  
42  
43 72. Van Der Miesen AI, Hurley H, De Vries AL. Gender dysphoria and autism spectrum  
44 disorder: A narrative review. *Int Rev Psychiatry*. 2016;28(1):70-80.  
45  
46 73. Hawthorne G, Korn S, Richardson J. Population norms for the AQoL derived from the  
47 2007 Australian National Survey of Mental Health and Wellbeing. *Aust N Z J Public Health*.  
48 2013;37(1):7-16.  
49  
50 74. Furber G, Segal L. The validity of the Child Health Utility instrument (CHU9D) as a  
51 routine outcome measure for use in child and adolescent mental health services. *Health Qual Life*  
52 *Outcomes*. 2015;13(1):1.  
53  
54

## **AUTHORS' CONTRIBUTIONS**

55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## **FUNDING STATEMENT**

The Trans20 study is supported by the RCH Foundation.

## COMPETING INTERESTS STATEMENT

The authors have no conflicts of interest to declare.

## WORD COUNT

Abstract: 299

Main text (excluding table): 4190

## ACKNOWLEDGEMENTS

We would like to acknowledge Associate Professor Sam Winter, Dr Riki Lane, Associate Professor Ruth McNair, Associate Professor Cathrine Mihalopoulos, Professor David Coghill, as well as the RCHGS team for their intellectual input into the Trans20 study design. We would also like to thank the RCHGS Consumer Advisory Group for providing feedback about the Trans20 proposal and for providing input into the instruments used in Trans20 and the preferred methods of data collection.

## FIGURE LEGENDS

### Figure 1. Clinical pathway at the RCHGS and integrated questionnaire administration


Note: \*Indicates data collection timepoint for Trans20; <sup>φ</sup> Following initial attendance at MDAC, questionnaires are repeated on an annual basis

### Figure 1 Legend

Legend

Clinical stage
Interventions offered
Trans20 Assessment

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



119x152mm (300 x 300 DPI)

# BMJ Open

## What are the health outcomes of trans and gender diverse young people in Australia? Study protocol for the Trans20 longitudinal cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032151.R2
Article Type:	Protocol
Date Submitted by the Author:	19-Sep-2019
Complete List of Authors:	Tollit, Michelle; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Pace, Carmen; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Telfer , Michelle ; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne Hoq, Monsurul ; Murdoch Children's Research Institute, Clinical Epidemiology and Biostatistics Unit Bryson, Janet ; Murdoch Childrens Research Institute Fulkoski, Nicholas ; Murdoch Childrens Research Institute Cooper, Charlie; Murdoch Childrens Research Institute Pang, Ken; Murdoch Childrens Research Institute; Royal Children's Hospital Melbourne
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Health services research, Paediatrics
Keywords:	Sexual and gender disorders < PSYCHIATRY, PAEDIATRICS, MENTAL HEALTH

SCHOLARONE™  
Manuscripts

# What are the health outcomes of trans and gender diverse young people in Australia? Study protocol for the Trans20 longitudinal cohort study

**Authors:** Michelle A Tollit<sup>1,2,3</sup>, Carmen C Pace<sup>1,2,4</sup>, Michelle M Telfer<sup>1,2,4</sup>, Monsurul Hoq<sup>1</sup>, Janet Bryson<sup>1</sup>, Nicholas Fulkoski<sup>1</sup>, Charlie Cooper<sup>1</sup>, Ken Pang<sup>1,2,4,5,6</sup>

**Affiliations:**

1. Murdoch Children's Research Institute, Melbourne, Victoria, Australia
2. The Royal Children's Hospital, Department of Adolescent Medicine, Melbourne, Victoria, Australia
3. Melbourne Graduate School of Education, The University of Melbourne, Parkville, Victoria, Australia
4. Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
5. Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
6. The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

## To whom correspondence should be addressed:

Dr Michelle Tollit  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [michelle.tollit@mcri.edu.au](mailto:michelle.tollit@mcri.edu.au)  
Ph: +61 3 9345 6903

Dr Ken Pang  
Murdoch Children's Research Institute  
Royal Children's Hospital  
Flemington Road, Parkville 3052  
Email: [ken.pang@mcri.edu.au](mailto:ken.pang@mcri.edu.au)  
Ph: +61 3 9345 5986

## ABSTRACT

Introduction: Being transgender is frequently accompanied by gender dysphoria, which often co-exists with mental health concerns. Increased referrals of transgender and gender diverse (TGD) youth to gender clinics have been observed in many countries. Nevertheless, there is limited empirical data on the presentation and outcomes of these patients, and there is an urgent need for more evidence to ensure optimal medical and psychosocial interventions. Here we describe Trans20, a longitudinal study of TGD patients attending a multidisciplinary paediatric gender service in Melbourne, Australia. Trans20 aims to understand the demographic and clinical characteristics of these patients, to document the natural history of gender diversity presenting in childhood, and to investigate long-term outcomes for those receiving interventions.

Methods and analysis: Trans20 is a prospective cohort study based on children and adolescents first seen at the Royal Children's Hospital Gender Service (RCHGS) between February 2017 and February 2020. Current estimates indicate the final sample size will be approximately 600. Patients and their parents complete online questionnaires prior to the first appointment with RCHGS and regularly thereafter as part of routine clinical care. Upon discharge from RCHGS patients are invited to continue undertaking questionnaires biennially. In this way, a naturally forming cohort study has been created. The primary outcomes include gender dysphoria, physical and mental health, schooling, family functioning and quality of life. Subgroup analyses based on factors such as gender identity, birth-assigned sex and treatment received will be performed using bivariate and multivariate modelling as appropriate, and relevant statistical methods will be applied for the repeated measures over time.

Ethics and dissemination: The Royal Children's Hospital Human Research Ethics Committee approved this study (#36323). Findings from Trans20 will have translational impact by informing future treatment guidelines and gender affirming healthcare practices, and will be disseminated through conferences and peer reviewed journals.

### Strengths and limitations of this study

- Multiple domains including gender, mental health, physical health, schooling, family functioning and quality of life will be prospectively documented in a large cohort of TGD children and adolescents.
- Trans20 will represent one of the largest and most comprehensive longitudinal studies of TGD young people in the world, with potential to make a significant contribution to better understanding and improving the health of TGD children and adolescents globally.
- The long term follow-up of pre-pubescent children will allow examination of the natural history of gender diversity from an early age in a clinically referred population, enabling clinicians to provide accurate prognostic information to patients and families, and therefore assist decision-making around social and legal transition for TGD young people.
- Due to ethical reasons, it is not possible to incorporate an untreated control group in the Trans20 study design; this will limit the potential to draw direct conclusions about the effectiveness of interventions but, where possible, measures with population-based data are used in Trans20 to compare outcomes of TGD youth with those of the general population.

## INTRODUCTION

In recent times there has been an increase in the number of individuals identifying as transgender (1) and those seeking gender affirming healthcare (2). This rise may in part be related to increased social acceptance of gender diversity and the growing recognition that being transgender is part of the continuum of gender diversity. Despite these shifts in societal attitudes, being transgender is frequently accompanied by gender dysphoria (GD). GD is the distress that arises when a person's birth-assigned sex does not match their gender identity. GD experienced in childhood and adolescence can be particularly challenging as young people are navigating a range of physical, social and emotional changes during this critical developmental period. Serious psychiatric disorders are very common, with rates of self-reported depression and anxiety diagnoses in TGD young people in Australia as high as 75% and 72% respectively, and 80% reporting ever self-harming and 48% ever attempting suicide (3). Experiences of bullying, physical assault, discrimination and social exclusion are also common for transgender individuals (3-6), and these experiences are likely to contribute to poor mental health.

Accompanying the rise in reported prevalence of TGD young people has been a rapid increase in referrals to specialist gender clinics across the Western world (7-10). Many TGD children and adolescents and their families seek help from healthcare professionals requesting support, advice and gender affirming psychosocial and medical treatments. Best practice clinical guidelines (11-13) promote a multidisciplinary approach to address the complex biopsychosocial needs of this group, and treatment is ideally tailored to a young person's developmental stage and individual needs. Psychosocial support is central to assist the young person and their parents to understand and explore their gender identity and, where appropriate, help to facilitate social transition, which may involve adoption of gender-affirming hairstyles, clothing, names, and pronouns. For children and adolescents, psychological support can also be an important intervention for treating co-existing mental health issues, while helping to navigate the relational, social and personal challenges associated with their gender identity. For children who have not reached puberty – some of whom present with significant GD as young as age three – medical intervention is not warranted, but for older children and adolescents, medical interventions may serve an important role alongside psychosocial support and can take several forms. First, medications known as GnRH analogues (“puberty blockers”) can help to prevent the development of undesired physical changes during puberty, which can trigger and/or exacerbate GD. Secondly, gender affirming hormones, namely oestrogen and testosterone, can help promote physical changes congruent with the young person's gender identity. Thirdly, surgical procedures, such as chest reconstructive surgery for transmasculine individuals (“top surgery”), are performed on adolescents in some centres (14, 15), while genital surgery is generally only performed after the age of majority.

Specific healthcare for TGD children and adolescents – including the use of medical interventions – is relatively new, having commenced only in the past two decades. Consequently, there is a need for more empirical data to inform best practice in important areas such as risk and protective factors, and the long-term safety and outcomes of medical interventions (12, 16, 17). Another key area for which stronger evidence is required relates to the natural history of gender diversity. While some parents of TGD youth report noticing signs of gender diversity from as young as age two (18), not all gender diverse children develop a transgender identity. Published literature reports that 45-88% of children with gender concerns in childhood go on to identify with their birth-



1  
2  
3 assigned sex in adolescence and adulthood (19-23) indicating that only some of these children  
4 report a transgender identity when older. A number of methodological, interpretative and ethical  
5 concerns have been raised about these studies (19), and they are now thought to underestimate the  
6 persistence of TGD identities from childhood to adolescence. Given this uncertainty, there is a  
7 clear need to better understand these trajectories in order to inform and guide decision making in  
8 this area for young people and their families.  
9

10  
11 Various research groups around the world have been attempting to fill these important knowledge  
12 gaps via longitudinal cohort studies of TGD children and adolescents. The longest running of these  
13 has been based at VU University Medical Centre in the Netherlands, which pioneered the use of  
14 medical interventions for TGD youth and has provided much of the currently available empirical  
15 data in the field (24). More recently, an NIH-funded study commenced in the US and is aiming to  
16 follow 280 transgender youth over five years (25). The study is recruiting across four separate  
17 clinical sites, each of which have their own treatment protocols and practices. There is a clear need  
18 for additional international cohorts to sit alongside these established studies.  
19  
20

21  
22 This paper describes the creation of a new longitudinal study of TGD children and adolescents,  
23 known as Trans20. Following a large cohort of patients who have attended the state-wide Royal  
24 Children's Hospital Gender Service (RCHGS) in Melbourne, Australia, Trans20 is designed to  
25 synthesize prospectively-gathered clinical data collected from patients during their time with and  
26 after they leave the RCHGS. The RCHGS employs a consistent assessment and treatment approach  
27 to its trans healthcare, meaning that Trans20 is ideally placed to avoid the difficulties inherent in  
28 studies that recruit across multiple sites where treatment approaches may vary.  
29  
30

31 In the context of this background, the Trans20 study primarily aims to:  
32

- 33  
34 i) Describe the demographic and clinical characteristics of TGD young people who attend  
35 healthcare services for gender-related concerns  
36  
37 ii) Identify clinical outcomes following different types of gender-affirming interventions  
38 (both psychosocial and medical)  
39  
40 iii) Identify risk and protective factors associated with physical and mental health outcomes of  
41 TGD children and adolescents  
42  
43 iv) Characterize the natural history of TGD young people, including those who differ in their  
44 presentations.  
45

46  
47 Trans20 seeks to contribute to the evidence underpinning healthcare for TGD young people, and  
48 thus not only inform prognosis but also improve clinical management and decision making.  
49

## 50 51 **METHODS AND ANALYSIS**

### 52 53 **Study design**

54  
55 Trans20 is a prospective, longitudinal cohort study, with a sample comprising patients aged 3-17  
56 years when first attending the RCHGS between February 2017 and February 2020. Online  
57 questionnaires are routinely administered as part of standard clinical care at RCHGS and are  
58 completed by patients and a nominated parent/primary caregiver prior to the first appointment with  
59  
60

1  
2  
3 the service, and then at regular periods thereafter (Figure 1). Some questionnaires are also  
4 administered by clinicians during the patients' clinical consultations, and these are referred to as  
5 "in-clinic questionnaires" hereafter. Patients who leave the service are invited to continue  
6 undertaking questionnaires biennially. In this way, a naturally forming cohort study has been  
7 created, and our intention is to continue follow-up over a 20-year period.  
8  
9

## 10 **Study setting**

11  
12 This study is based at the RCHGS in Melbourne, Australia. The RCHGS provides publicly-funded  
13 assessment and gender affirming care to TGD young people throughout the state of Victoria.  
14 RCHGS staff come from a range of clinical specialties and disciplines including psychology,  
15 psychiatry, paediatrics, endocrinology, gynaecology, speech therapy and nursing. With  
16 approximately 250 new referrals each year, RCHGS is the largest multidisciplinary gender service  
17 for children and adolescents in Australia. Young people up to age 17 years who reside in Victoria  
18 and have concerns regarding their gender identity can be referred to RCHGS by their general  
19 practitioner. Patients subsequently enter the service via one of two pathways: the Under 8 clinic  
20 for those aged 7 years and below, or the First Assessment Single Session Triage (FASST) clinic  
21 for those aged 8 years and older. Patients attending the Under 8 clinic are assigned a mental health  
22 clinician for initial assessment and support, and those wishing to undertake a medical transition  
23 are later referred to a member of the paediatric team prior to onset of puberty. Patients attending  
24 the FASST clinic see a Clinical Nurse Consultant or an Adolescent Medicine fellow (doctor  
25 undergoing advanced pediatric training) for initial assessment and support; those who wish to  
26 receive further psychosocial support and/or medical intervention are subsequently seen in the  
27 Multidisciplinary Assessment Clinic (MDAC) (Figure 1). Regardless of which pathway a patient  
28 enters, they and their parents undertake an assessment which includes the completion of  
29 standardised questionnaires prior to their first appointment, and these assessments are repeated at  
30 regular (~12 monthly) intervals as patients continue to attend the service.  
31  
32  
33  
34  
35

## 36 **Participants and eligibility**

37  
38 To be eligible for inclusion in Trans20, participants need to have attended an initial appointment  
39 with the RCHGS between February 2017 - February 2020, have completed at least one of the  
40 baseline questionnaires (i.e., patient questionnaire, parent questionnaire, or in-clinic  
41 questionnaire), and speak sufficient English to complete the questionnaires. Since patients can be  
42 referred to the RCHGS at any age before 18 years, participants are expected to range in age from  
43 3-17 years at study entry. Data from the first two years of the study indicate that on the day of first  
44 appointment with the RCHGS, the large majority of patients (75.3%) were aged 12 years or older,  
45 18.6% were aged 6-11 years and 6.1% were aged 5 years or younger. Based on those meeting  
46 eligibility for involvement in Trans20 in the first two years, it is expected that the Trans20 cohort  
47 will comprise approximately 600 participants over the three-year enrolment period.  
48  
49  
50  
51

## 52 **Ethics, recruitment and consent**

53  
54 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
55 the conduct of this study (#36323). As previously outlined, questionnaires are completed by  
56  
57  
58  
59

1  
2  
3 patients and parents as part of routine clinical care at RCHGS, and this information will be  
4 analysed under a clinical audit framework. As Trans20 is designed to prospectively collect data  
5 from patients beyond their time with the RCHGS, long-term follow up of patients who leave the  
6 RCHGS requires specific consent. Consent is obtained using a multi-step procedure, from parents  
7 for those aged under 18 years, and from young people themselves once they are aged 18 years or  
8 older. At the time of undertaking assessments with the RCHGS, permission to contact patients and  
9 their families about the Trans20 study in the future is prospectively collected. Following discharge,  
10 those who have provided consent to be contacted are then invited to continue to undertake  
11 assessments. For patients who have left the service and are under 18 years, an email with parent  
12 and participant information statements as well as questionnaire links are sent to the nominated  
13 parent, who are asked to pass the relevant documentation to their child if they consent to them  
14 being involved. Patients who have left the service and are 18 years or older are sent these directly  
15 via email. Under each of these scenarios, completion of the online questionnaires provides implied  
16 consent. Consent to contact treating clinicians to obtain physical health information will also be  
17 sought for those who no longer attend the RCHGS.  
18  
19  
20

### 21 **Data collection and storage**

22  
23  
24 Parent and patient questionnaires are administered via LimeSurvey, an online, open source, survey  
25 web application (26), supported by the RCH for clinical use. Separate parent and patient  
26 questionnaire links are sent to a parent email address, and parents and patients complete the  
27 questionnaires online. Questionnaires are administered approximately one month prior to patients'  
28 initial appointment with the service, and then at approximately 12 month intervals throughout their  
29 RCHGS episode of care. Information on community supports are provided at the end of all  
30 questionnaires. Participants (who no longer attend the RCHGS) who disclose information that  
31 raises concern about a significant risk of harm will be contacted by project staff to provide  
32 additional support. This may include: discussing additional support services, encouraging the  
33 participant to contact their general practitioner and/or access existing supports and referring the  
34 participant to external supports (including mental health triaging services) where appropriate. The  
35 information statements that accompany the surveys, advises parents and participants that they may  
36 be contacted for this purpose. If individuals remain upset after completing questionnaires they are  
37 also advised to call the RCHGS to help organize support.  
38  
39  
40

41 In-clinic questionnaires – which cover topics such as drug use, sexual health, self-harm and  
42 suicidality - are asked directly of patients at an appropriate age by clinicians during their  
43 appointments and responses are later entered into LimeSurvey. These questions are asked by  
44 clinicians during appointments to ensure timely and appropriate follow-up if required. Having  
45 been introduced by their clinicians, these questions are subsequently asked of patients in their  
46 online follow-up questionnaires, with clinicians applying appropriate follow-up for current  
47 patients as deemed clinically relevant.  
48  
49  
50

51 Parent, patient and in-clinic questionnaire responses (and scored summary data where relevant)  
52 are uploaded to patients' electronic medical record (EMR) and the RCHGS Clinical Database  
53 (DRN #DB089). Thus, these are available to their treating team to help guide assessment and  
54 treatment. For those who consent to being part of Trans20 following discharge from the RCHGS,  
55 follow-up questionnaires are administered via LimeSurvey and stored in the RCHGS Clinical  
56  
57  
58  
59  
60

1  
2  
3 Database. For those discharged from RCHGS a \$20 gift voucher will be offered as a sign of  
4 appreciation and as reimbursement for the time spent completing the surveys.  
5

6  
7 Data from this study are stored securely on RCH servers in password-protected files that can only  
8 be accessed by study personnel. Data will be stored for 7 years post-study closure, or until the  
9 youngest participant turns 25 years old, and will then be securely destroyed. Data will be stored  
10 in a re-identifiable format, with participants given a unique, re-identifiable code that maps to  
11 identifying information, including hospital record number.  
12

### 13 **Measures**

14  
15  
16 Trans20 questionnaire measures were selected to provide information relevant to the assessment  
17 and treatment of GD and related co-morbidities. Measures span multiple domains including  
18 gender, mental health, education, quality of life, parental wellbeing, family functioning, as well as  
19 their experience of care at RCHGS. In addition to measuring core gender-related and mental health  
20 outcomes, broader indicators of health and wellbeing were also included to holistically and  
21 comprehensively assess multifaceted functioning (including at school and within the family) which  
22 may be related to gender and mental health outcomes in this group. Where possible, measures with  
23 strong psychometric properties and good reliability and validity were chosen. Some measures are  
24 appropriate only for specific age groups or birth-assigned sex, and the online questionnaires are  
25 tailored accordingly. A full list of Trans20 questionnaire measures is provided in Table 1, and each  
26 measure – grouped by domain - is described in further detail below.  
27  
28

#### 29 *Demographics and past history*

30  
31  
32 Standard demographic data and information related to the young person's medical and  
33 developmental history are routinely collected in the questionnaires. These items were developed  
34 by the study investigators; some demographic questions relating to English proficiency,  
35 Indigenous status and religious affiliation were based on standards recommended by the Australian  
36 Bureau of Statistics (ABS) (27). From age 18 years, individuals are asked questions about  
37 education and employment based on ABS Census questions (28).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Measures used in Trans20 in parent, patient and in-clinic questionnaires.

	Construct	Instrument	Reference	Parent Q'aire	Patient Q'aire	In-clinic Q'aire	Age range****
<b>Demographics &amp; History</b>							
	Demographics	Introducing you	(27, 28) T20 PT	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: all ages – no age restrictions
	Medical history	Medical and developmental history	T20 PT	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 18+
<b>Gender</b>							
	Gender identity and supports	About your gender – Gender Slider	T20 PT		√		All ages – no age restrictions
	Social transitioning	About socially transitioning	T20 PT	√	√		Parent report: 0-7 Patient report: 8+
	Voice	About your voice	(29, 30)		√		12+
	Gender role behaviours & gender identity	Gender Identity Questionnaire	(31)	√			<=12
	Gender dysphoria	Single item measuring recent gender-related distress	T20 PT		√		All ages – no age restrictions
	Gender dysphoria: gender preoccupation & gender stability	Gender Preoccupation and Stability Questionnaire	(32)		√		11+
	Body image	Body Image Scale	(33)		√	√	12+
	Chest dysphoria	Chest Dysphoria Scale	(34)		√		12+ (birth-assigned females)
	Hormone treatment experiences**	Medical intervention treatment effects and satisfaction. Tanner's Sexual Maturation Scale	T20 PT (35-37)		√		12+ for those reporting that they have started puberty suppression or gender affirming hormones
<b>Mental Health</b>							
	Internalizing and externalizing behavior	Youth Self Report	(38)		√		11-18
		Preschool Child Behavior Checklist	(39)	√			1.5-5
		School-age Child Behavior Checklist	(38)	√			6-18
	Anxiety symptomatology	Spence Children's Anxiety Scale –Preschool	(40)	√			3-5
		Spence Children's Anxiety Scale -Parent report	(41)	√			6-18
		Spence Children's Anxiety Scale - Self report	(42-44)		√		7-18
	Eating disorders	Branched Eating disorder Test	(45)		√		12+
	Depressive symptomatology	Short Mood and Feelings Questionnaire	(46)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS***. Patient report: 7+
	Depression, anxiety and stress	Depression Anxiety Stress Scales -21 (DASS21)	(47)		√		Patient report: 18+
	Social phobia	Social Phobia Scale	(48)		√		18+

	Resilience: pride and connectedness	The Gender Minority Stress and Resilience Measure	(49)		√		Patient report: 12+
	Resilience	The Brief Resilience Scale	(50)		√		Patient report: 8+
	Self-harm	Self-harm questions based on Hawton et al (2002)	(51)		√	√	12+
	Suicidality	Columbia-Suicide Severity Rating Scale	(52)		√	√	12+
	Autism features*	Social Responsiveness Scale 2: School-age form	(53)	√			4-18
<b>School Functioning</b>							
	School attendance	About school (school type, attendance)	(54)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 18+
	Academic performance	School-age Child Behavior Checklist	(38)	√			6-18
	School connectedness	Psychological Sense of School Membership Survey	(55)		√		12-18
<b>Bullying &amp; Discrimination</b>							
	Bullying	Gatehouse Bullying Scale	(56)		√		8-18
	Discrimination	Adapted from the Victorian Population Health Survey	(57)	√			18+
<b>Family Functioning</b>							
	Family functioning	Family Assessment Device -General Functioning scale	(58, 59)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 12+
<b>Quality of Life</b>							
	Quality of life (patient)	Child Health Utility 9D	(60, 61)	√	√		Parent report: <=5 Patient report: 6+
		The Assessment of Quality of Life (AQoL) - 4D	(62, 63)		√		18+
	Parental quality of life	The Assessment of Quality of Life (AQoL) - 4D	(62, 63)	√			All ages – no age restrictions while patient at RCHGS***
<b>Drug use and Sexual Health</b>							
	Health risk behaviors	Tobacco, alcohol and drug use	(64-67)		√	√	12+
	Sexuality	Attraction and relationship questions. Adapted from the Victorian Population Health Survey	T20 PT (57)		√	√	12+
<b>Clinical experiences</b>							
	Discharge status**	Reasons for discharging from RCHGS	T20 PT	√	√		For those discharged from RCHGS Parent report: <=11 Patient report: 12+
	Experiences of care**	RCHGS Experiences of care	(68-71)	√	√		Parent report: all ages – no age restrictions while patient at RCHGS*** Patient report: 12+

\*only asked at initial assessment \*\*only asked at follow-up assessments; \*\*\*Not administered to parent if young person is aged 18 years (or older) and discharged from RCHGS ; \*\*\*\* age range refers to the age of TGD youth at which questionnaires are asked of either the TGD youth and/or their parent; T20 PT = Trans20 project team devised questions; Q'aire = Questionnaire.

## Gender

1  
2  
3 Different aspects of gender identity are assessed using various complementary tools including the  
4 Gender Identity Questionnaire (31), Gender Preoccupation and Stability Questionnaire (32) and  
5 the Gender Slider. The Gender Slider, developed by the Trans20 project team in consultation with  
6 the RCHGS, is a visual analogue scale to help patients describe their gender identity. This tool  
7 consists of two continuous scales, male and female, where individuals move the slider on each  
8 scale to reflect their gender identity, from 'not at all' to 'completely'. The Body Image Scale (33)  
9 provides information on body dissatisfaction. An item developed by the Trans20 team is used to  
10 measure extent of GD. The Social Transition Questionnaire (developed by the Trans20 team)  
11 assesses the extent to which an individual has socially transitioned. The Gender Voice  
12 Questionnaire (adapted from the Transsexual Voice Questionnaire (29, 30)) and the Chest  
13 Dysphoria Scale (administered to birth-assigned females) (34) provide information on voice  
14 dysphoria and chest dysphoria respectively. In combination, these tools enable the examination  
15 of shifts in gender identity, expression and dysphoria over time. Additional questions devised by  
16 the project team about the effects of hormonal treatment are asked of those who have been treated  
17 with hormones.  
18  
19  
20

### 21 *Mental health*

22  
23  
24 Mental health is assessed longitudinally using well-validated measures chosen for their common  
25 use in this population. The Child Behavior Checklist (CBCL) and Youth Self Report (38, 39)  
26 assess behavioural and emotional problems across broad domains including: anxious/depressed,  
27 withdrawn/depressed, somatic complaints, social problems, thought problems, attention problems,  
28 rule-breaking behaviour, and aggressive behaviour. The Short Mood and Feelings Questionnaire  
29 (46) and Spence Children's Anxiety Scale (40-44) focus on depressive and anxiety  
30 symptomatology respectively. In young adulthood, the DASS21 (47) is used to measure  
31 depression, anxiety and stress while social phobia is measured using the Social Phobia Scale (48).  
32 The Gender Minority Stress and Resilience Measure (community connectedness and pride scales)  
33 (49) and the Brief Resilience Scale (50) measure resilience. Assessment of self-harm is based on  
34 an established self-harm questionnaire (51), and the Columbia-Suicide Severity Rating Scale (52)  
35 assesses suicidality. A modified version of the Branched Eating Disorders Test (45) is  
36 administered to assess disordered eating. Given the frequent co-occurrence of autism in gender  
37 diverse individuals (72), the Social Responsiveness Scale-2 (53) is used to screen for features of  
38 autism at the initial assessment.  
39  
40  
41

### 42 *Education/school functioning*

43  
44  
45 Trans20 examines a range of educational outcomes over time. Academic achievement is measured  
46 using relevant questions within the CBCL (38, 39). School connectedness is assessed using the  
47 Psychological Sense of School Membership survey (55). School absenteeism is determined using  
48 modified questions from the Longitudinal Study of Australian Children (54). Finally, bullying is  
49 evaluated using the Gatehouse Bullying Scale (56) and supplemented with specific items inquiring  
50 about cyberbullying. Young adults are asked about experiences of discrimination based on  
51 questions from the Victorian Population Health Survey (57).  
52  
53

### 54 *Quality of life and family functioning*

1  
2  
3 The Child Health Utility 9D (CHU 9D) (60, 61) and the Assessment of Quality of Life Instrument  
4 (AQoL-4D) (62, 63) are administered to determine how GD and its associated difficulties impact  
5 on child and parental quality of life respectively. These tools are generic quality of life measures  
6 used frequently in health economic assessments of disease impact. Australian population-based  
7 norms and utility weights exist for the AQoL-4D and CHU-9D respectively (73, 74). Family  
8 functioning is measured using the General Functioning 12-item subscale of The McMaster Family  
9 Assessment Device (58, 59).

### 12 *Drug use and sexual health*

14  
15 Adolescents and young adults are asked about current and lifetime alcohol, cigarette and illegal  
16 drug use, using questions adapted from the CTC survey (64-66) and the Childhood to Adolescence  
17 Transition Study (67), while sexual health information (including attraction, relationship status,  
18 current sexual activity) is gathered via items developed by the Trans20 team and items based on  
19 the Victorian Population Health Survey (57).

### 22 *Experiences of care*

24  
25 Young people (aged 12 and older) and all parents are asked about experiences of care at the  
26 RCHGS, using a questionnaire adapted from those in use at adult gender services in the US, UK,  
27 and Australia (68-71). Following discharge from the RCHGS, participants are asked the reason for  
28 discharge.

### 30 *Physiology*

32  
33 To determine the physical effects of puberty blockers and gender affirming hormones, RCHGS  
34 clinicians routinely monitor a variety of physiological parameters, including height, weight, body  
35 mass index, blood pressure, bone mineral density, luteinising hormone, follicle stimulating  
36 hormone, testosterone, oestrogen, liver function, haemoglobin, serum cholesterol, and  
37 haemoglobin A1c at regular intervals consistent with the Australian Standards of Care and  
38 Treatment Guidelines for Trans and Gender Diverse Children and Adolescents (13). These data  
39 are stored within the EMR (for current patients) and can be directly extracted to facilitate analysis.  
40 Patients on puberty blockers and gender affirming hormones are reviewed by clinicians  
41 approximately every 3-6 months, and we will routinely extract physical health information  
42 generated from these appointments from patients' medical record. For those who no longer attend  
43 the RCHGS, this information will be sought from patients' current treating clinician, at  
44 approximately the same time as their scheduled online assessments.

### 47 **Sample size**

49  
50 In the first 24 months of Trans20, 397 young people were considered eligible for involvement in  
51 Trans20. Assuming similar rates for the final 12 months of the three-year enrolment period, it is  
52 expected that the total sample will comprise approximately 600 patients. Taking this into  
53 consideration, the starting sample size is large enough to estimate with 90% power a minimum  
54 difference of 6% between two proportions or a minimum difference of .3 standard deviation  
55



1  
2  
3 between two means of two equal size groups. The statistical power may not be the same for unequal  
4 or subgroup analysis.  
5

6  
7 To estimate attrition, the number of questionnaires completed before an MDAC (or 12 months  
8 post FASST) were examined relative to those who had completed questionnaires before their  
9 FASST appointment across the first 24 months of Trans20, resulting in a retention rate of 83%.  
10 Based on these figures, it is anticipated that 498 young people will continue completing  
11 questionnaires post the three-year recruitment period.  
12

### 13 14 **Data analysis plan** 15

16 Relevant clinical outcomes (gender dysphoria, mental health, physical health, schooling, family  
17 functioning and quality of life) will be described using appropriate univariate statistics and by  
18 subgroups such as gender identity, birth-assigned sex and treatment status using bivariate statistics.  
19 Multivariate models such as linear regression or logistic regression will be used for continuous or  
20 bivariate measures respectively to explore the relationship between physiological and clinical  
21 outcomes with gender identity adjusting for covariates. Appropriate statistical methods will be  
22 applied to analyse the repeated measures of factors over time, their effect on the outcomes  
23 including missing data if necessary.  
24  
25

### 26 27 **Patient and public involvement** 28

29 The RCHGS Consumer Advisory Group comprises children, adolescents and young adults who  
30 identify as TGD, families of those who identify as TGD, as well as representatives from  
31 organizations that work with or support the trans community. The RCHGS Consumer Advisory  
32 Group was consulted about the Trans20 proposal and provided input into the instruments used in  
33 Trans20 and the preferred methods of data collection. The Consumer Advisory Group will  
34 continue to be consulted to ensure that this research is conducted in a way that best suits the needs  
35 of the trans, gender diverse and non-binary community.  
36  
37

### 38 39 **ETHICS AND DISSEMINATION** 40

41 The Royal Children's Hospital Human Research Ethics Committee (HREC) granted approval for  
42 the conduct of this study (#36323).  
43

44 Findings from Trans20 will have translational impact by informing future treatment guidelines and  
45 gender affirming healthcare practices. It is expected that findings from the Trans20 study will be  
46 presented at conferences and published in peer reviewed journals.  
47  
48

### 49 50 **DISCUSSION** 51

52 Providing optimal clinical care for TGD young people is critical, but there is a need for stronger  
53 empirical research data to inform clinical practice in this emerging field. The Trans20 study has  
54 been established to examine biopsychosocial outcomes of TGD individuals attending a large,  
55 multidisciplinary paediatric gender service. The majority of data for Trans20 are collected  
56 prospectively as part of routine clinical care to assist clinicians in providing patient care, and  
57  
58  
59  
60

1  
2  
3 simultaneously offer an opportunity to address important research questions in the field of  
4 transgender child and adolescent health.  
5

6  
7 Several features of Trans20 are worth highlighting. First, the longitudinal nature of the study,  
8 spanning childhood, adolescence and young adulthood will allow a number of critical questions to  
9 be addressed. The answers to these will shed light on trajectories of gender identity development  
10 in early life, risk and protective factors related to health outcomes, and the safety and effectiveness  
11 of psychosocial and hormonal interventions. Secondly, the collected data has significant breadth  
12 and depth, providing detailed information not only on gender identity, transition, dysphoria and  
13 gender-related healthcare, but also mental health, physical health, education, quality of life and  
14 family functioning, which will allow for a comprehensive range of outcomes to be examined.  
15 Thirdly, study participants are all from a single paediatric gender service that employs a consistent  
16 assessment and treatment approach and, in this way, Trans20 avoids some of the difficulties  
17 inherent in studies that recruit across multiple sites where treatment approaches may vary.  
18  
19

20  
21 Similar to other cohort studies, the issue of attrition should be considered in light of its potential  
22 to impact the generalizability and power of the study. Notwithstanding this, as the initial enrolment  
23 into Trans20 includes all patients attending the RCHGS who complete questionnaires, there is less  
24 likelihood of selection bias occurring as part of study recruitment. Furthermore, it is not ethically  
25 possible to incorporate an untreated control group in the Trans20 study design. This is because  
26 withholding treatment for the purposes of forming a comparison group may cause patients  
27 significant distress and therefore pose significant risk of harm to individuals. Absence of a control  
28 group will limit the potential to draw direct conclusions about the effectiveness of interventions  
29 but, where possible, measures with population-based data are used in Trans20 to compare  
30 outcomes of TGD youth with those of the general population.  
31  
32

33  
34 In conclusion, referrals of TGD children and adolescents for medical care have been increasing  
35 across the Western world, and the current demand for transgender health services may be just the  
36 tip of the iceberg. Looking ahead, it will be paramount to fill existing knowledge gaps and  
37 determine empirically how best to manage the care of TGD young people so that future best  
38 practice guidelines can be based on as much robust evidence as possible. In this regard, the Trans20  
39 study will provide critical information pertinent to clinical practice and its provision. It will provide  
40 integral information on the natural history of gender diversity, which will enable clinicians to  
41 provide accurate prognostic information to patients and families, and therefore assist decision-  
42 making around social and legal transition for TGD young people. The study will also provide  
43 important information on the benefits and risks of current clinical pathways which could be used  
44 to inform the TGD community about the long-term safety and outcomes of different forms of  
45 medical interventions available to them. Finally, the longitudinal nature of Trans20 will allow  
46 opportunities for targeted interventions to be identified, and ultimately help to improve care for  
47 this vulnerable population.  
48  
49  
50

## 51 52 53 **REFERENCES** 54 55 56 57 58 59 60

1. Meerwijk EL, Sevelius JM. Transgender population size in the United States: A meta-regression of population-based probability samples. *Am J Public Health*. 2017;107(2):e1-e8.
2. Goodman M, Adams N, Cornell T, et al. Size and distribution of transgender and gender nonconforming populations: A narrative review. *Endocrinol Metab Clin North Am*. 2019;48(2):303-21.
3. Strauss P, Cook A, Winter S, et al. *Trans Pathways: The Mental Health Experiences and Care Pathways of Trans Young People. Summary of Results*. Perth, Australia: Telethon Kids Institute; 2017.
4. Earnshaw VA, Bogart LM, Poteat VP, et al. Bullying among lesbian, gay, bisexual, and transgender youth. *Pediatr Clin North Am*. 2016;63(6):999-1010.
5. Huffaker L, Kwon P. A comprehensive approach to sexual and transgender prejudice. *J Gay Lesbian Soc Serv*. 2016;28(3):195-213.
6. Winter S, Diamond M, Green J, et al. Transgender people: Health at the margins of society. *The Lancet*. 2016;388(10042):390-400.
7. Heard J, Morris A, Kirouac N, et al. Gender dysphoria assessment and action for youth: Review of health care services and experiences of trans youth in Manitoba. *Paediatr Child Health*. 2017;23(3):179-84.
8. The Tavistock and Portman NHS Foundation Trust. GIDS referrals increase in 2017/18 2018 [Available from: <http://gids.nhs.uk/news-events/2018-05-16/gids-referrals-increase-201718>].
9. Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. *Pediatrics*. 2012:418-25.
10. Telfer M, Tollit M, Feldman D. Transformation of health-care and legal systems for the transgender population: The need for change in Australia. *J Paediatr Child Health*. 2015;51(11):1051-3.
11. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. *Int J Transgend*. 2012;13(4):165-232.
12. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869-903.
13. Telfer MM, Tollit MA, Pace CC, et al. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. *Med J Aust*. 2018;209(3):132-6.
14. Marinkovic M, Newfield RS. Chest reconstructive surgeries in transmasculine youth: Experience from one pediatric center. *Int J Transgend*. 2017;18(4):376-81.
15. Milrod C, Karasic DH. Age is just a number: WPATH-affiliated surgeons' experiences and attitudes toward vaginoplasty in transgender females under 18 years of age in the United States. *J Sex Med*. 2017;14(4):624-34.
16. Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms -- Meeting the health needs of transgender people. *N Engl J Med*. 2016;375(2):101-3.
17. Chew D, Anderson J, Williams K, et al. Hormonal treatment in young people with gender dysphoria: A systematic review. *Pediatrics*. 2018;141(4).
18. Ehrensaft D. Raising girlyboys: A parent's perspective. *Stud Gen Sex*. 2007;8(3):269-302.
19. Temple Newhook J, Pyne J, Winters K, et al. A critical commentary on follow-up studies and "desistance" theories about transgender and gender-nonconforming children. *Int J Transgend*. 2018:1-13.

- 1
- 2
- 3
- 4 20. Drummond KD, Bradley SJ, Peterson-Badali M, et al. A follow-up study of girls with
- 5 gender identity disorder. *Dev Psychol*. 2008;44(1):34.
- 6 21. Steensma TD, Biemond R, de Boer F, et al. Desisting and persisting gender dysphoria after
- 7 childhood: A qualitative follow-up study. *Clin Child Psychol Psychiatry*. 2011;16(4):499-516.
- 8 22. Steensma TD, McGuire JK, Kreukels BP, et al. Factors associated with desistence and
- 9 persistence of childhood gender dysphoria: a quantitative follow-up study. *J Am Acad Child*
- 10 *Adolesc Psychiatry*. 2013;52(6):582-90.
- 11 23. Wallien MS, Cohen-Kettenis PT. Psychosexual outcome of gender-dysphoric children. *J*
- 12 *Am Acad Child Adolesc Psychiatry*. 2008;47(12):1413-23.
- 13 24. de Vries A, McGuire J, Steensma T, et al. Young adult psychological outcome after puberty
- 14 suppression and gender reassignment. *Pediatrics*. 2014;134:696-704.
- 15 25. Reardon S. Largest ever study of transgender teenagers set to kick off. *Nature News*.
- 16 2016;531(7596):560.
- 17 26. Limesurvey GmbH. LimeSurvey: An Open Source survey tool. Hamburg, Germany:
- 18 LimeSurvey GmbH.
- 19 27. McLennan W. Standards for Statistics on Cultural and Language Diversity. Canberra:
- 20 Australian Bureau of Statistics; 1999.
- 21 28. Australian Bureau of Statistics. Census Household Form 2016. Available from:
- 22 [http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/\\$FILE/2016](http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/$FILE/2016%20Census%20Sample%20Household%20Form.pdf)
- 23 [%20Census%20Sample%20Household%20Form.pdf](http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/2901.0Main%20Features802016/$FILE/2016%20Census%20Sample%20Household%20Form.pdf).
- 24 29. Dacakis G, Davies S, Oates JM, et al. Development and preliminary evaluation of the
- 25 transsexual voice questionnaire for male-to-female transsexuals. *J Voice*. 2013;27(3):312-20.
- 26 30. Davies SM, Johnston JR. Exploring the validity of the transsexual voice questionnaire for
- 27 male-to-female transsexuals. *Canadian Journal of Speech-Language Pathology and Audiology*
- 28 2015;39(1):40-51.
- 29 31. Johnson LL, Bradley SJ, Birkenfeld-Adams AS, et al. A parent-report gender identity
- 30 questionnaire for children. *Arch Sex Behav*. 2004;33(2):105-16.
- 31 32. Hakeem A, Črnčec R, Asghari-Fard M, et al. Development and validation of a measure for
- 32 assessing gender dysphoria in adults: The Gender Preoccupation and Stability Questionnaire. *Int*
- 33 *J Transgend*. 2016;17(3-4):131-40.
- 34 33. Lindgren TW, Pauly IB. A body image scale for evaluating transsexuals. *Arch Sex Behav*.
- 35 1975;4(6):639-56.
- 36 34. Olson-Kennedy J, Warus J, Okonta V, et al. Chest reconstruction and chest dysphoria in
- 37 transmasculine minors and young adults: Comparisons of nonsurgical and postsurgical cohorts.
- 38 *JAMA Pediatr*. 2018;172(5):431-6.
- 39 35. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. *Arch Dis*
- 40 *Child*. 1969;44(235):291.
- 41 36. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. *Arch Dis*
- 42 *Child*. 1970;45(239):13-23.
- 43 37. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of
- 44 adolescent development. *J Youth Adolesc*. 1980;9(3):271-80.
- 45 38. Achenbach T, Rescorla LA. Manual for the ASEBA School-Age Forms & Profiles.
- 46 Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
- 47 39. Achenbach T, Rescorla LA. Manual for the ASEBA Preschool Forms & Profiles.
- 48 Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2000.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

40. Edwards SL, Rapee RM, Kennedy SJ, et al. The assessment of anxiety symptoms in preschool-aged children: The revised preschool anxiety scale. *J Clin Child Adolesc Psychol*. 2010;39(3):400-9.
41. Nauta MH, Scholing A, Rapee RM, et al. A parent-report measure of children's anxiety: Psychometric properties and comparison with child-report in a clinic and normal sample. *Behav Res Ther*. 2004;42(7):813-39.
42. Spence SH. A measure of anxiety symptoms among children. *Behav Res Ther*. 1998;36(5):545-66.
43. Spence SH. Structure of anxiety symptoms among children: A confirmatory factor-analytic study. *J Abnorm Psychol*. 1997;106(2):280.
44. Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents. *J Anxiety Disord*. 2003;17(6):605-25.
45. Selzer R, Hamill C, Bowes G, et al. The branched eating disorders test: Validity in a nonclinical population. *Int J Eat Disord*. 1996;20(1):57-64.
46. Angold A, Costello EJ, Messer SC, et al. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. *Int J Methods Psychiatr Res*. 1995.
47. Lovibond SH, Lovibond PF. *Manual for the Depression Anxiety Stress Scales*. (2nd Ed.). Sydney: Psychology Foundation; 1995.
48. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. *Behav Res Ther*. 1998;36(4):455-70.
49. Testa RJ, Habarth J, Peta J, et al. Development of the gender minority stress and resilience measure. *Psychol Sex Orientat Gend Divers*. 2015;2(1):65.
50. Smith BW, Dalen J, Wiggins K, et al. The brief resilience scale: Assessing the ability to bounce back. *Int J Behav Med*. 2008;15(3):194-200.
51. Hawton K, Rodham K, Evans E, et al. Deliberate self harm in adolescents: Self report survey in schools in England. *BMJ*. 2002;325(7374):1207-11.
52. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry*. 2011;168(12):1266-77.
53. Constantino J, Gruber C. *The Social Responsiveness Scale Manual, Second Edition (SRS-2)*. Los Angeles, CA: Western Psychological Services.; 2012.
54. Daraganova G. Is it OK to be away? School attendance in the primary school years. *The Longitudinal Study of Australian Children Annual Statistical Report: Australian Institute of Family Studies*; 2012.
55. Goodenow C. The psychological sense of school membership among adolescents: Scale development and educational correlates. *Psychol Sch*. 1993;30(1):79-90.
56. Bond L, Wolfe S, Tollit M, et al. A comparison of the Gatehouse Bullying Scale and the Peer Relations Questionnaire for students in secondary school. *J Sch Health*. 2007;77(2):75-9.
57. Victorian Agency for Health Information. *Victorian Population Health Survey 2017*. Melbourne: VAHI; 2019.
58. Epstein NB, Baldwin LM, Bishop DS. The McMaster family assessment device. *J Marital Fam Ther*. 1983;9(2):171-80.
59. Miller IW, Epstein NB, Bishop DS, et al. The McMaster family assessment device: reliability and validity. *J Marital Fam Ther*. 1985;11(4):345-56.

- 1  
2  
3 60. Stevens K. Assessing the performance of a new generic measure of health-related quality  
4 of life for children and refining it for use in health state valuation. *Appl Health Econ Health Policy*.  
5 2011;9(3):157-69.  
6  
7 61. Stevens K. Valuation of the child health utility 9D index. *Pharmacoeconomics*.  
8 2012;30(8):729-47.  
9  
10 62. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL)  
11 instrument: A psychometric measure of health-related quality of life. *Quality of Life Research*.  
12 1999;8(3):209-24.  
13  
14 63. Richardson J, Hawthorne G. The Australian quality of life (AQoL) instrument:  
15 Psychometric properties of the descriptive system and initial validation. *Australian Studies in*  
16 *Health Service Administration*. 1998;85:315-42.  
17  
18 64. Pollard JA, Hawkins JD, Arthur MW. Risk and protection: Are both necessary to  
19 understand diverse behavioral outcomes in adolescence? *Soc Work Res*. 1999;23(3):145-58.  
20  
21 65. Glaser RR, Horn MLV, Arthur MW, et al. Measurement properties of the Communities  
22 That Care® Youth Survey across demographic groups. *J Quant Criminol*. 2005;21(1):73-102.  
23  
24 66. Arthur MW, Hawkins JD, Pollard JA, et al. Measuring risk and protective factors for use,  
25 delinquency, and other adolescent problem behaviors: The Communities That Care Youth Survey.  
26 *Eval Rev*. 2002;26(6):575-601.  
27  
28 67. Mundy LK, Simmons JG, Allen NB, et al. Study protocol: The childhood to adolescence  
29 transition study (CATS). *BMC Pediatr*. 2013;13(1):160.  
30  
31 68. Bockting W, Robinson B, Benner A, et al. Patient satisfaction with transgender health  
32 services. *J Sex Marital Ther*. 2004;30(4):277-94.  
33  
34 69. Davies A, Bouman WP, Richards C, et al. Patient satisfaction with gender identity clinic  
35 services in the United Kingdom. *Sex Relation Ther*. 2013;28(4):400-18.  
36  
37 70. Erasmus J, Bagga H, Harte F. Assessing patient satisfaction with a multidisciplinary gender  
38 dysphoria clinic in Melbourne. *Australas Psychiatry*. 2015;23(2):158-62.  
39  
40 71. Wylie KR, Fitter J, Bragg A. The experience of service users with regard to satisfaction  
41 with clinical services. *Sex Relation Ther*. 2009;24(2):163-74.  
42  
43 72. Van Der Miesen AI, Hurley H, De Vries AL. Gender dysphoria and autism spectrum  
44 disorder: A narrative review. *Int Rev Psychiatry*. 2016;28(1):70-80.  
45  
46 73. Hawthorne G, Korn S, Richardson J. Population norms for the AQoL derived from the  
47 2007 Australian National Survey of Mental Health and Wellbeing. *Aust N Z J Public Health*.  
48 2013;37(1):7-16.  
49  
50 74. Furber G, Segal L. The validity of the Child Health Utility instrument (CHU9D) as a  
51 routine outcome measure for use in child and adolescent mental health services. *Health Qual Life*  
52 *Outcomes*. 2015;13(1):1.  
53  
54

## 55 **AUTHORS' CONTRIBUTIONS**

56 KP, MAT, MMT and CP conceptualized the design of the study. MH devised the analysis plan.  
57 JB, CC, and NF helped to implement the study. MAT drafted the manuscript. All authors reviewed  
58 and edited the manuscript and approved the final manuscript.  
59

## 60 **FUNDING STATEMENT**

The Trans20 study is supported by the RCH Foundation.

## COMPETING INTERESTS STATEMENT

The authors have no conflicts of interest to declare.

## WORD COUNT

Abstract: 299

Main text (excluding table): 4256

## ACKNOWLEDGEMENTS

We would like to acknowledge Associate Professor Sam Winter, Dr Riki Lane, Associate Professor Ruth McNair, Associate Professor Cathrine Mihalopoulos, Professor David Coghill, as well as the RCHGS team for their intellectual input into the Trans20 study design. We would also like to thank the RCHGS Consumer Advisory Group for providing feedback about the Trans20 proposal and for providing input into the instruments used in Trans20 and the preferred methods of data collection.

## FIGURE LEGENDS

### Figure 1. Clinical pathway at the RCHGS and integrated questionnaire administration


Note: \*Indicates data collection timepoint for Trans20; <sup>φ</sup> Following initial attendance at MDAC, questionnaires are repeated on an annual basis

### Figure 1 Legend

Legend

Clinical stage
Interventions offered
Trans20 Assessment

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1.** Clinical pathway at the RCHGS and integrated questionnaire administration  
 Note: \*Indicates data collection timepoint for Trans20; φ Following initial attendance at MDAC, questionnaires are repeated on an annual basis

Figure 1. Clinical pathway at the RCHGS and integrated questionnaire administration  
 215x279mm (300 x 300 DPI)